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Herbal medicine, the backbone of traditional medicine, has played an important role in human health
and welfare for a long period. Traditional therapeutic approaches of regional signiﬁcance are found in
Africa, South and Central America, China, India, Tibet, Indonesia, and the Paciﬁc Islands. The considerable
scientiﬁc signiﬁcance and commercial potential of traditional medicines have resulted in increased in-
ternational attention and global market demands for herbal medicines, especially Chinese herbal med-
icines. Herbal medicines currently are the primary form of health care for the poor in the developing
countries, and also are widely used as a supplement or substitute for conventional drugs in developed
countries. These traditional medicines have a pivotal role in the treatment of various ailments and more
than 50% of drugs used in Western pharmacopoeia are isolated from herbs or derived from modiﬁcations
of chemicals found in plants. Herbal medicines usually contain a complex mixture of various bioactive
molecules, which make its standardization complicated, and there is little information about all com-
pounds responsible for pharmacological activity. Several research papers have been published that claim
pharmacological activity of herbal medicines but few are discussing the role of the exact phytocon-
stituent. Understanding the pharmacokinetic proﬁle of such phytoconstituents is essential. Although
there are research papers that deal with pharmacokinetic properties of phytoconstituents, there are a
number of phytoconstituents yet to be explored for their kinetic properties. This article reviews the
pharmacokinetic proﬁle of 50 different therapeutically effective traditional medicinal plants from the
year 2003 onward.
Copyright © 2014, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. All rights reserved.1. Introduction
Herbal medicines are known to have a strong reputation
throughout history and within every culture to provide ﬁrst-line
and basic health services for patients with numerous disease
conditions. The roots of herbal medicine are at the very beginning
of human history. These are the oldest form of medicine for welfare
of mankind, and they play a paramount role in culture-speciﬁc
traditional medicinal systems (TMS), i.e., Ayurveda (India) andceutical Chemistry, Bharati
rmacy, Pune 411 038, Maha-
dasan).
for Food and Biomolecules,
molecules, National Taiwan Univetraditional Chinese medicine (China). Herbal medicine is an
umbrella term that encompasses an array of treatment options to
supplement conventional and nonconventional therapies. Herbal
medicine approaches are completely different from modern or-
thodox medicines. The historical background of herbal medicine
begins with ethnopharmacology, a term introduced in 1967, which
mainly deals with the scientiﬁc study of the traditional medicinal
plants. It can be deﬁned as ʻthe scientiﬁc study of materials used by
ethnic and cultural groups as medicinesʼ and in most instances this
is synonymous with the study of traditional medicine.1 Phyto-
chemicals, phytomedicine, natural remedies, natural products and
their chemistry, and various other subjects are present in the realm
of herbal medicines and are beyond the scope of this article.
Basically, medicinal plants are a huge source of chemical com-
pounds, including primary and secondary metabolites, alkaloids,
ﬂavonoids, and lignin. These medicinal plants and their extractsrsity. Production and hosting by Elsevier Taiwan LLC. All rights reserved.
Table 1
Pharmacokinetic parameters after oral administration of visnagin.
Parameters Values
Peak plasma concentration (Cmax) (ng/mL) 2969
Time of peak plasma concentration (Tmax) (h) 0.33
Area under the concentration-time curve) (trapezoidal rule)
(h  mg/L)
11.9
Apparent clearance (CL/F) (L/kg) 0.84
The terminal elimination half-life (h) 2.3
Table 2
Pharmacokinetic parameter of 3-n-butylphthalide after intravenous administration
dose 5 mg/kg.
Parameter Values
AUC0-6h (ng$h/mL) 1140.16
Apparent volume of distribution (Vc) (L/kg) 1.22
Half-life (t1/2) (distribution) (h) 0.098
t1/2 (elimination) (h) 2.62
Clearance (Cl) (L/h kg) 3.67
AUC ¼ area under the concentration-time curve.
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medicinal system. These natural bioactive compounds play a cen-
tral role in combating many human diseases. More than 50% of
drugs used in Western pharmacopoeia are isolated from herbs or
derived from modiﬁcation of phytoconstituents.2 Recent studies
have stated that 75e90% (developing world) and 80% (less devel-
oped/developing countries) of the current world population relies
on the use of herbal medicines for their primary health care and
other needs, which signiﬁes the scope of TMS, where 85% of me-
dicinal plants of TMS involve the use of plant extracts.3,4 These
phytochemicals show a more complex pharmacokinetic proﬁle
(the study of the time course of phytochemicals, absorption, dis-
tribution, metabolism, and excretion). This pharmacokinetic proﬁle
helps to elaborate the relationship between intensity and time
course of pharmacology, the toxicological effects of phytochemicals
in the human body, and extends the scope of the use and accep-
tance by different regulatory bodies. As pointed out by the World
Health Organization, there is very limited knowledge about the
chemical compositions, pharmacokinetics, pharmacodynamics,
and metabolomics of TCM plants; the data about authentication,
efﬁcacy, and safety of TCM are known and are far from satisfactory
to meet the required criteria for worldwide use.5 To provide
satisfactory data about safety and efﬁcacy of these medicinal plants
and for pharmacokinetic proﬁle, we have gathered information
from various search engines and other possible sources from 2003
onward to provide a detailed picture on ADME parameters
(absorption, distribution, metabolism, and excretion) of some
phytoconstituents. The review elaborates pharmacokinetic proﬁle
of 50 medicinally important phytoconstituents from different
medicinal plants.
2. Pharmacokinetic proﬁle of drugs
2.1. Ammi visnaga L. (阿密茴香 e mì huí xiang)
Visnagin is a furanocoumarins derivative and one of the major
constituents in Ammi visnaga L. (Apiaceae). It is commonly known
as Khella. It was used by ancient Egyptians as a treatment for kidney
stone disease. Visnagin has cardiovascular effects due to calcium
channel blocking actions. Visnagin also has negative chronotropic
and inotropic effects and reduces peripheral vascular resistance. Its
extract prevents urolithiasis (kidney stone formation) by
decreasing calcium oxalate crystal growth in the stone-forming rat
model.
A sensitive and highly selective liquid chromatography-tandem
mass spectrometry (LC-MS) method was used to determine vis-
nagin in rat plasma. Chromatography was performed on a Phe-
nomenex Synergi Max RP, (75  2.0 mm internal diameter [i.d.],
4 mm, Torrance, CA, USA) analytical column at ambient tempera-
ture. The mobile phase used for analysis was 0.1% formic acid, 5mM
ammonium acetate in deionized water and methanol (15:85, v/v)
delivered at a ﬂow rate of 0.2 mL/min. For quantitative determi-
nation of visnagin in a rat plasma, a 50-mL sample is required.
Pharmacokinetic parameters after oral administration of visnagin
are provided in Table 1.6
2.2. Apium graveolens, Ligusticum sinensis, and Ligusticum
wallichii (芹菜 qín cai), Ligusticum sinensis (藁本 gǎo ben) and
Ligusticum wallichii (川芎 chuan xiong)
3-n-Butylphthalide is a volatile chemical present in several
plants including Apium graveolens, Ligusticum sinensis, and Ligu-
sticum wallichii. In China 3-n-butylphthalide [(±)-NBP] may be a
promising new drug for the treatment of ischemic cerebral dis-
eases, such as stroke.A high-performance liquid chromatography (HPLC)-mass spec-
trometry (MS)/MS with positive ionization mode was adopted to
determine 3-n-butylphthalide in rat plasma. The system was
equipped with an ACQUITY UPLCTM BEH C18 (50  2.1 mm i.d.,
1.7 mm) column. Gradient mobile phase composed of acetonitrile
(ACN) and water containing 0.1% formic acid was used. The sepa-
rated compounds were detected by a Waters Tandem Quadrupole
(TQ) Detector (Waters, Milford, MA). The column temperature, ﬂow
rate, and chromatographic run time per sample used was 35C,
0.2 mL/min, and 3.0 minutes, respectively. The lower limit of
quantiﬁcation (LLOQ) value was 5.57 ng/mL. Pharmacokinetic pa-
rameters after intravenous administration of 3-n-butylphthalide
(5 mg/kg) are provided in Table 2.7 3-n-Butylphthalide followed
extensive metabolism in humans and produced four metabolites,
i.e., 10-keto-NBP, 3-hydroxy-NBP, 10-hydroxy-NBP, and NBP-11-oic
acid.8
2.3. Atractylodes macrocephala Koidz (白朮 bai zhú)
Atractylodes macrocephala Koidz is one of the TCMs listed in
Chinese pharmacopoeia. It exhibits antitumor, anti-inﬂammatory,
and antibacterial properties. The anticancer effect of atractyleno-
lide I has been proved in different cancer cells.
The HPLC-MS/MS method was reported for quantiﬁcation of
atractylenolide I in Wistar rat plasma after oral administration of
the ethanolic (95%) extract of atractylodis. The MS was operated in
the positive electrospray ionization (ESI) mode with multiple re-
action monitoring (MRM). The LC system was equipped with a
Phenomenex Gemini column (2.0  50 mm i.d., 5 mm, Phenomenex
Company, CA, USA). Themobile phase consisted of a mixture of 0.1%
formic acid inwater and 0.1% formic acid in methanol. The ﬂow rate
was set at 0.4 mL/min, and column temperature and injection
volume are 25C and 10 mL, respectively. The limit of detection
(LOD) and the limit of quantiﬁcation (LOQ) are 0.6 ng/mL and
2.0 ng/mL, respectively. The pharmacokinetic parameters of atrac-
tylenolide I after oral administration of ethanolic (95%) atractylodis
extract are presented in Table 3. The pharmacokinetic data indicate
that atractylenolide I was absorbed very quickly in the body.
When simultaneous determination for atractylenolide I, II, and
III was performed in blank rat plasma, atractylenolide II was found
in real samples, atractylenolide III was found in plasma at different
time points, and the pharmacokinetic curve of atractylenolide III
showed an irregular pattern.9
Table 3
Pharmacokinetic parameters of atractylenolide I after oral administration of
Atractylodis extract (20 g/kg) to rats (n ¼ 6, mean ± standard deviation).
Parameters Values
Elimination rate constant (Ke) (/h) 0.365 ± 0.06
AUC0-T (mg h/L) 22.2 ± 1.9
AUC0-∞ (mg h/L) 22.6 ± 1.8
Tmax (h) 0.81 ± 0.11
Cmax (mg/L) 7.99 ± 1.2
Vc (l/kg) 2768.6 ± 751.5
Cl (l/h/kg) 978.2 ± 117.3
t1/2 (h) 1.94 ± 0.27
AUC ¼ area under the concentration-time curve; Cl ¼ clearance; Cmax ¼ peak
plasma concentration; Tmax ¼ time of peak plasma concentration.
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Artemisia annua L. (annual wormwood) contains the antima-
larial artemisinin. Aqueous preparations of the dried herb are
included in the pharmacopoeia of the People's Republic of China for
the treatment of fever and malaria.
A reverse-phase HPLC was used to determine artemisinin in
blood samples of healthy male volunteers receiving 9 g of Artemisia
annua L. The system is equipped with 250  4.6 mm Multophere
RP-18, 5-mm column (Chromatography Service, Langenwehe, Ger-
many). A linear gradient of 45e100% acetonitrile in water (20 mi-
nutes, 1 mL/min) was used. For online postcolumn derivatization,
0.3M aqueous potassium hydroxidewas added to the elute at a rate
of 0.2 mL/min. The resulting mixture was passed through a 5-m
steel capillary (0.5 mm internal diameter) immersed in a water
bath of 70C. Ultraviolet absorption was monitored at 289 nm. The
pharmacokinetic parameters of artemisinin are provided in Table 4.
The overall picture of pharmacokinetic data revealed that artemi-
sinin plasma concentrations after intake of the given herbal tea are
sufﬁcient for clinical effects, but insufﬁcient to recommend such
preparations as equivalent substitutes for modern artemisinin
drugs in malaria therapy.10
2.5. Aristolochia fangchi (防己馬兜鈴 fang jǐ mǎ dou líng)
Aristolochic acids (AAs) are found primarily in the plant genera
Aristolochia and Asarum. AAs exhibit anti-inﬂammatory, antitus-
sive, and antiplatelet aggregation pharmacologic properties and
they are also used as pain relievers. AAs have proved to be themajor
components that cause renal ﬁbrosis problems. AAs are a mixture
of structural-related 10-nitrophenanthrene 1-carboxylic acids,
where AAI, the 8-methoxy-3,4- methylene dioxy derivative, and
AAII, the 3,4-methylenedioxy derivative, are the major components
in the Aristolochia species.
Ultra high-performance liquid chromatography (UHPLC)-MS/
MS with a Quatro Micro triple-quadrupole mass spectrometer
(Micromass, Manchester, UK) operating at positive ion electrospray
mode has been reported to determine the pharmacokinetic pa-
rameters. The system was equipped with an Acquity BEH C18Table 4
Pharmacokinetic parameters of artemisinin.
Parameter Values
Mean ± SD (ng/mL)
(Maximum plasma concentration of artemisinin)
240 ± 75
Mean ± SD (ng/mL  h)
(Area under the plasma concentration-time curve)
336 ± 71
Tmax (h) 0.6 ± 0.2
t1/2 (h) 0.9 ± 0.2
SD ¼ standard deviation; Tmax ¼ time of peak plasma concentration.column (100  2.1 mm i.d., 1.7 mm, Waters) for separation of aris-
tolochic acids. The mobile phase was composed of 10mM ammo-
nium formaten (pH 3.0) (solvent A) and ACN (solvent B). The
gradient proﬁle was 0e2 min: 34% B; 2e10.5 min: linear from 34%
to 36% B; 10.5e10.6 min: linear from 36% to 34% B and then re-
equilibrium of the column. The ﬂow rate was kept at 0.3 mL/min.
The column oven and autoinjection system are set at 40C and 4C
respectively. Partial loop with needle over ﬁll mode was used for
sample injection, and the injection volume was 5 mL. The LOD was
0.14 ng/mL for AAI and 0.26 ng/mL for AAII. The pharmacokinetic
parameters after single oral administration of 10 mg/kg standard in
female Wistar rats are presented in Table 5.
The pharmacokinetic data revealed that AAs could be quickly
absorbed in the gastro-intestinal tract. The hepatic enzymes P450
1A1 and 1A2 help to detoxify AAI through the metabolism of AAI
into less toxic metabolites aristolactam I (AL I).112.6. Anemarrhena asphodeloides (知母 zhı mǔ)
The Chinese herb named as Zhi-Mu, mangiferin (2-b-D-gluco-
pyranosyl-1,3,6,7-tetrahydroxyxanthen-9-one) has been isolated
from the herbal root of Anemarrhena asphodeloides Bung showing
antioxidant, antiviral, and anticancer activity.
A HPLC tandem MS with in vivomicrodialysis sampling method
was used for continuous monitoring of free mangiferin in rat blood.
Mangiferin was separated by a reverse-phase C microbore column
(15031 mm) from dialysate within 10 minutes. The mobile phase
consisted of 18 acetonitrile-0.05% phosphoric acid-tetrahydrofuran
(10:75:15, v/v/v) with a ﬂow rate of 0.05 mL/min. The wavelength
of the UV detector was set at 257 nm. The LOQ and retention time
are 0.05mg/mL and 6.0 minutes, respectively. The pharmacokinetic
parameters formangiferin are provided in Table 6. The study results
revealed that mangiferin cannot cross the blood-brain barrier
because it was not detected in the bile and brain for all dosage
treatments. Mangiferin metabolites are formed by methylation and
phase II sulfation and glucuronidation are found in rat bile.122.7. Baphicacanthus cusia (Nees) Bremek. (馬藍 mǎ lan),
Polygonum tinctorium Ait. (蓼藍 liǎo lan) and Isatis indigotica Fort.
(菘藍 song lan)13
Indirubin, a 3,20-bisindole isomer of indigo, exists in several
medicinal plants such as Baphicacanthus cusia (Nees) Bremek,
Polygonum tinctorium Ait., and Isatis indigotica Fort. It is one of the
compounds that exhibits antileukemic action more speciﬁcally
effective against chronic granulocytic leukemia. In addition, it is
useful as an antiproliferative and an anti-inﬂammatory agent.
HPLC was adopted to determine the pharmacokinetic parame-
ters of indirubin in a rat after intravenous and intraperitoneal
administration. It was equipped with a Zirchrom Kromasil ODS
column (200  4.6 mm i.d., 5 mm) and protected by a guardTable 5
Pharmacokinetic parameters after single oral administration of 10 mg/kg standard
in female Wister rats.
Parameter AAI AAII
T max (min) 30 45
C max (ng/mL1) 7249.3 77.7
AUC (ng/mL1 min) 716,936.3 31,344.8
t1/2 (min) 234.6 800.7
Rate constant (k) (min1) 0.003 0.0009
Oral clearance (mL/min1) 2.9 66.0
AA¼ aristolochic acid; AUC¼ area under the concentration-time curve; Cmax¼ peak
plasma concentration; Tmax ¼ time of peak plasma concentration.
Table 6
Pharmacokinetic parameters following mangiferin administration (10, 30, and
100 mg/kg, intravenously) (± ¼ 6).
Parameters 10 mg/kg 30 mg/kg 100 mg/kg
AUC (min mg/mL) 122.9617.1 452.5639.8 2424.26196.7a
Half-life of slow distribution phase
(t 1/2b) (min)
28.563.5 35.063.5 47.864.1* 1/2,b
Steady-state volume of distribution
(Vss) (L/kg)
3.060.3 2.560.3 2.060.3 ss
Cl (mL/min/kg) 90.161 2.6 69.166.5 43.264.3*
Mean residence time (min) 35.062.52 35.962.8 45.864.8*
AUC ¼ area under the concentration-time curve; Cl ¼ clearance.
* Denotes the, signiﬁcantly different (p ¼ 0.05) from the dose of 10 and 30 mg/kg
(Student's t test) and SS denotes the steady-state.
a Signiﬁcantly different (p ¼ 0.05) from the dose of 10 and 30 mg/kg
(Student t test).
Table 8
The main pharmacokinetic parameters of CXB after a single intravenous adminis-
tration of 5.0 mg/kg CXB in six male rats.
Parameter Value
Vc (L/kg) 2.60 ± 1.88
t1/2 pi (h) 0.109 ± 0.058
Half-life of rapid distribution phase (t1/2 a) (h) 0.503 ± 0.173
t1/2 b (h) 8.17 ± 0.99
K12 (1/h) 1.38 ± 1.36
k21 (1/h) 2.24 ± 1.77
k13 (1/h) 1.17 ± 0.178
k31 (1/h) 0.113 ± 0.021
k10 (1/h) 4.53 ± 1.65
Cl (L/kg/h) 9.52 ± 1.73
AUC0et (ng h/mL) 566.0 ± 76.4
AUC0e∞ (ng h/mL) 583.1 ± 79.7
AUC ¼ area under the concentration-time curve; Cl ¼ clearance.
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Cheshire, UK). The mobile phase contains a mixture of methanol-
water (75:25, v/v). The ﬂow rate and wavelength for detection
are 1 mL/min and 289 nm at room temperature, respectively. The
LLOQ was found to be 6.5 ng/mL. The mean pharmacokinetic pa-
rameters of indirubin after intravenous injections and intraperi-
toneal injections at doses 2.8, 5.6, and 5.6 mg/kg, respectively, in
rats are provided in Table 7. The parent molecule of indirubin
metabolized and excreted fast as compared with its metabolites.
Indirubin showed a relatively low bioavailability of 8.40% in rats
when it was intraperitoneally administered, and to enhance its
therapeutic efﬁcacy design of appropriate dosage form or delivery
system or structural modiﬁcation may be required.
2.8. Cudrania tricuspidata (Carr.) Bur. (柘樹 zhe shù)
Cudrania tricuspidata (Carr.) Bur. is a deciduous shrub or tree
distributed over China, Korea, and Japan. The root of the plant is
used for gastric carcinoma. Among the active compounds, cudra-
tricusxanthone B (CXB) is found to be the most promising.
A HPLC-ESI-tandem MS was used to evaluate the pharmacoki-
netic characteristics of CXB after intravenous administration in the
rat. The system was equipped with a Venusil XBP-PH C18 column
(2.1  100 mm i.d., 5 mm) coupled with a Phenomenex C18 guard
column (4.0  3.0 mm i.d., 5 mm) and the temperature was set at
40C. The mobile phase was 0.5% formic acid in methanol at a ﬂow
rate of 0.3 mL/min. Acquisition of MS data for CXB and Internal
standards was performed in positive ionization mode. The study
used 5.0 mg/kg CXB in rats, which was administered via the tail
vein. Blood samples (about 50 mL at 0.083 and 0.25 h, and about
200 mL at other points) are drawn from the retro-orbital plexus
before dosing and at 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 9, 15, and 24 hours
after dosing. The compartment model for pharmacokineticTable 7
Mean pharmacokinetic parameters of indirubin after intravenous injections at doses
of 5.6 and 2.8 mg/kg and intraperitoneal injections at dose of 5.6 mg/kg in rats.
Parameters Doses
5.6 mg/kg (i.v.) 2.8 mg/kg (i.v.) 5.6 mg/kg (i.p.)
AUC0eN (ng h/mL) 308 ± 750.0 130 ± 748.3 25.9 ± 74.9
AUC0et (ng h/mL) 295 ± 745.2 124 ± 7 43.3 22.6 ± 75.2
Cmax (ng/mL) 201 ± 723.7 155 ± 717.7 20.87 ± 7.6
Tmax (h) 0.017 0.017 0.010
Ke (h1) 0.670 ± 70.2 0.6837 ± 0.2 0.6407 ± 0.5
t1/2 (h) 1.0307 ± 0.2 1.0207 ± 0.2 1.08070 ± .4
MRT (h) 1.7507 ± 0.3 1.5107 ± 0 .3 0.7777 ± 1.1
AUC¼ area under the concentration-time curve; Cmax¼ peak plasma concentration;
i.p. ¼ intraperitoneal; i.v. ¼ intravenous; MRT ¼ mean residence time; Tmax ¼ time
of peak plasma concentration.parameters of CXB was chosen according to the lowest Akaike in-
formation criterion (AIC) value. The (AUC0-t) and inﬁnity (AUC0-∞)
are calculated using the linear trapezoidal rule with a non-
compartment model, and other parameters are estimated with a
three-compartment model. The method was sensitive with an
LLOQ at 1.0 ng/mL for CXB using 100 mL of rat plasma. The phar-
macokinetic parameters of CXB after a single intravenous admin-
istration are given in Table 8. CXB after a single intravenous
administration indicate the rapid distribution followed by a slow
elimination.14
2.9. Citrus depressa (Shiikuwasha) (扁實檸檬 biǎn shí níng meng),
Citrus sinensis (oranges) (甜橙 tian cheng) and Citrus limon
(lemons) (檸檬 níng meng)
Nobiletin (30,40,5,6,7,8,-hexamethoxyﬂavone) is a poly-
methoxylated ﬂavone commonly found in citrus fruit peels such as
Citrus depressa (shiikuwasa), Citrus sinensis (oranges), and Citrus
limon (lemons). Nobiletin exhibits a wide range of activities such as
anti-inﬂammatory, antitumor proliferation, antitumor invasion,
and neuroprotective properties and also is helpful in treating Alz-
heimer disease. In addition, nobiletin also improves hyperglycemia,
insulin resistance, and atherosclerosis. Nobiletin substantially
improve oral bioavailability in comparison with other poly-
hydroxylated ﬂavonoids.
HPLC coupled with Photodiode Array Detector (PDA) was used
to quantiﬁcation of nobiletin in rat plasma and brain tissue. The
system was equipped with Lichro CART RP18 column
(4.6  250 mm i.d., 5.0 mm). The system was run in isocratic mode
with mobile phase consisting of potassium dihydrogen ortho-
phosphate (pH 4.5; 0.04mM) and acetonitrile in ratio of 50:50, v/v.
The ﬂow rate and run time are 1.0 mL/min and 9.0 min, respec-
tively, at 334 nm. The LLOQ is 0.05 ng/mL. The pharmacokinetics
parameters of nobiletin in male S.D. rats following oral adminis-
tration of nobiletin are provided in Table 9. Nobiletin get rapidly
absorbed because of its lipophilic nature and high permeability.Table 9
Selected pharmacokinetics parameters of nobiletin in male Sprague Dawley rats
following oral administration of nobiletin at 50 mg/kg (n ¼ 3/time point).
Parameters Plasma Brain
AUC(0et) (mg$h/mL) 7.49 20.66
AUC(0e∞) (mg$h/mL) 7.84 23.20
Cmax (mg$h/mL) 1.78 4.20
Tmax (h) 1.00 1. 00
Kel (1/h) 0.39 0.06
t1/2 (h) 1.80 11.42
AUC¼ area under the concentration-time curve; Cmax¼ peak plasma concentration;
Tmax ¼ time of peak plasma concentration; Kel ¼ elimination rate constant.
Table 11
Pharmacokinetic data after curcumin administration (10 mg/kg intravenously and
500 mg/kg by mouth) in rats.
Parameters Curcumin
10 mg/kg, i.v. 500 mg/kg, p.o.
AUC (min mg/mL) 7.2 ± 1.2 3.6 ± 0.6
t1/2 b (min) 28.1 ± 5.6 44.5 ± 7.5
Cmax (mg/mL) 0.36 ± 0.05 0.06 ± 0.01
Tmax (min) e 41.7 ± 5.4
AUC¼ area under the concentration-time curve; Cmax¼ peak plasma concentration;
i.v. ¼ intravenous; p.o. ¼ by mouth; Tmax ¼ time of peak plasma concentration.
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with plasma. The AUC and t1/2 indicated that the brain exposure of
nobiletin is approximately three times higher than the plasma.15
2.10. Cynomorium songaricum Rupr. (鎖陽 suǒ yang)
Cynomorium songaricum Rupr. (Suoyang) is one of the known
medicinal parasitic plants from TCM. The catechins isolated from
C. songaricum include catechin, epicatechin, and epicatechin
gallate. Catechin and epicatechin are useful in atherosclerosis and
cancer treatment, respectively.
The LC-MS/MS method was used for simultaneous determina-
tion of pharmacokinetic parameters catechin, epicatechin, and
epicatechin gallate after oral administration of alcoholic
C. songaricum extract in rats. The system was equipped with an
Eclipse Plus (Agilent, USA) C18 (4.6 100 mm,1.8 mm) columnwith
a security guard C18 (2.1 12.5 mm i.d., 5 mm) column. The mobile
phase involves formic acid aqueous solution (0.1%) (A) and aceto-
nitrile (B) using a gradient elution of 20e44% B at 0e8min, 44e80%
B at 8e12 min, 80e20% B at 12e13 min, and the re-equilibration
time of gradient elution is 5 minutes. The ﬂow rate, column oven
temperature, and injection volume are 0.3 mL/min, 25C, and 10 mL,
respectively. Cmax of catechin, epicatechin, and epicatechin gallate
in rat plasma are 86.69 ± 38.65, 32.57 ± 15.00 and 36.93 ± 12.62 ng/
mL whereas Tmax values are 0.15 ± 0.09, 0.20 ± 0.10 and 0.20 ± 0.13
hours, respectively. The LLOQ value is 2 ng/mL. The pharmacoki-
netic parameters of catechin, epicatechin, and epicatechin gallate
after oral administration are provided in Table 10. Catechin, epi-
catechin, and epicatechin gallate demonstrated rapid absorption in
rat plasma after oral administration of C. songaricum extracts.16
2.11. Curcuma longa L. (薑黃 jiang huang)
Curcumin(1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-
3,5-dione) is a phenolic substance derived from spice herb
Curcuma longa L. Curcumin is widely used in the food industry
as a natural food coloring agent and curry powder. In addition,
curcumin has the anticancer, antiviral, and anti-infectious
properties, anti-amyloidogenic effects, and wound healing
qualities and it is also useful in treating Alzheimer disease.
A LC-MS/MS with an orthogonal Z-spray electrospray interface
system was used to determine the pharmacokinetics and oral
bioavailability of curcumin and demethoxy curcumin from C. longa.
The system was equipped with a ZORBAX (Agilent, Palo Alto, CA,
USA) Extend-C18 column (150  4.6 mm i.d., 5 mm). The system
delivered a constant ﬂow of 200 mL/min and the mobile phase
consisted of 70% acetonitrile and 30% 1mM formic acid. The volume
of injection was 10 mL. The LOD and LOQ of curcumin in the rat
plasma are 1ng/mL and 5 ng/mL, respectively. It can also be used as
an analytical tool for the quality control of various species of
turmeric herbs. The pharmacokinetic data after curcumin admin-
istration are provided in Table 11.17 The extent of curcumin conju-
gation was greater in an intestine of human and in rat curcumin isTable 10
Pharmacokinetic parameters of catechin, epicatechin, and epicatechin gallate after
oral administration of 15.25 g kg1 C. songaricum extract (n ¼ 8, mean ± standard
deviation).
Parameters Catechin Epicatechin Epicatechin gallate
MRT0e12 (h) 3.98 ± 0.33 4.54 ± 0.66 3.85 ± 0.78
T1/2 2a(h) 0.33 ± 0.12 0.60 ± 0.34 0.51 ± 0.36
T1/2 2b(h) 6.38 ± 4.20 34.86 ± 25.30 4.70 ± 4.24
AUC0e12 (ng h/mL) 109.7 ± 57.0 67.66 ± 16.99 72.44 ± 49.93
AUC 0-∞ (ng h/mL) 154.0 ± 97.2 214.0 ± 161.7 91.01 ± 67.99
AUC ¼ area under the concentration-time curve; MRT ¼ mean residence time.widely conjugated in hepatic fraction. Intestinal and hepatic mi-
crosomes are responsible for curcumin glucuronide whereas cur-
cumin sulfate, tetrahydrocurcumin, and hexahydro-curcumin were
found as curcumin metabolites in intestinal and hepatic cytosol
from humans and rats.18
3. Dicaffeoylquinic acids
Dicaffeoylquinic acids (DCQAs) are a class of natural poly-
phenolic compounds widely distributed in many herbs. 3,4-DCQA,
1,5-DCQA, 3,5-DCQA, and 4,5-DCQA are the typical analogs of
DCQAs. Large amounts of such polyphenolic compounds have been
extracted from Ainsliaea fragrans champ. (兔耳風 tù er feng) These
compounds exhibit various biological actions such as antibacterial,
antiviral, anti-inﬂammatory, and antioxidative stress effects.
The HPLC-MS/MSmethodwas used for simultaneous estimation
of pharmacokinetic activity of four DCQAs in Dawley rat plasma.
The systemwas equippedwith an Agilent (Santa Clara, CA) ZORBAX
SB-C18 column (150  2.1 mm i.d., 1.8 mm) (Agilent Technologies).
The MS was operated in the negative mode. The mobile phase
composed of acetonitrile (A) and water containing 0.1% formic acid
(B) and it is eluted as follows: 0 min (23%, A), 2 minutes (23%, A), 3.5
minutes (10%, A), 5 minutes (20%, A), 10.5 minutes (20%, A), 14
minutes (70%, A), 14.01 minutes (23%, A), and 18 minutes (23%, A).
The ﬂow rate and column temperature were 0.2 mL/min and 30C,
respectively. The plasma sample was prepared using a liquid-liquid
extraction method and the recovery rate for the four analytes was
around 80%. The calibration curves are linear over a concentration
range of 10.6e1060.0 ng/mL for 3,4-DCQA, 19.2e1920.0 ng/mL for
1,5-DCQA, 14.0e2900.0 ng/mL for 3,5-DCQA, and 9.7e970.0 ng/mL
for 4,5-DCQA. The intraday and interday precision was less than
15% and the relative error (RE) was within ±15%. The four DCQAs
were not stable after three complete freeze/thaw cycles (80C to
23C). However, they were stable after long-term sample storage
(80C for 30 days) and bench-top (23C for 2 hours). The extracted
samples on the auto sampler rack at 4C are stable for 6 hours. The
LLOQ was as follows: 10.6 ng/mL for 3,4-DCQA, 19.2 ng/mL for
1,5-DCQA, 14 ng/mL for 3,5-DCQA, and 9.7 ng/mL for 4,5-DCQA,
which was sufﬁciently sensitive to measure relatively low con-
centrations of DCQA in plasma with a simple liquid-liquid extrac-
tion procedure using as little as 50 mL plasma. The typical plasma
concentration-time proﬁles indicate that 3,4-DCQA, 3,5- DCQA, and
4,5-DCQA may transform to 1,5-DCQA in vivo because the content
of 1,5-DCQA in the extract was very low.19
3.1. Dracaena cochinchinensis (龍血 long xue)
Longxuejie is a resina moiety isolated from the Dracaena
cochinchinensis (Lour.) S.C. Chen which is also called ʻdragon's
bloodʼ in TCM. Longxuejie is clinically used in the treatment of
cerebral arterial thrombosis, ischemic heart disease, and peptic
ulcer. Loureirin B is the single active component isolated form of
longxuejie that has shown good therapeutic actions.
Table 13
Pharmacokinetic parameters of protodioscin in rats after intravenous
administrations.
Parameter Dose (mg/kg)
0.5 1 3
t1/2 (min) 78 ± 12 58 ± 11 27 ± 19
kel (1/min) 0.0089 ± 0.0056 0.012 ± 0.042 0.029 ± 0.009
Cmax (mg/mL) 70 ± 9 116 ± 15 378 ± 10
Vss (mL/kg) 71.6 ± 13 49 ± 21 23.5 ± 9
Cl (mL/min/kg) 0.637 ± 0.19 0.598 ± 0.05 0.681 ± 0.06
AUC0-t (mg min/mL) 732 ± 82 1406 ± 107 4196 ± 245
AUC0e∞ (mg min/mL) 785 ± 94 1673 ± 195 4406 ± 209
AUC¼ area under the concentration-time curve; Cl¼ clearance; Cmax¼ peak plasma
concentration; Vss ¼ volume of distribution at steady state.
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was used to analyze the Loureirin B after oral administration of
longxuejie. The MS was operated in the positive ESI mode with
multiple reaction monitoring (MRM) at unit resolution. The system
was equipped with an Agilent XDB-C18 column (4.6  50 mm i.d.,
5 mm) maintained at 20C. The mobile phase was composed of
water containing 0.1% formic acid (A) andmethanol containing 0.1%
formic acid (B) and with ﬂow rate of 0.4 mL/min. After oral
administration of 16 g/kg longxuejie to rats through lavage, serial
blood samples (0.3 mL) are collected by retro-orbital puncture at 0,
0.083, 0.17,0.33, 0.5, 0.75, 1, 2, 4, 6, 8, 12, and 18 hours, and then
centrifuged at 5000 rpm for 5 minutes immediately afterward. All
plasma samples are stored at 20C until analysis. The concen-
tration range of 0.08e100 ng/mL. The LOD and LOQ were 0.03 and
0.08 ng/mL, respectively. The pharmacokinetic parameters of
loureirin B after oral administration of longxuejie are provided in
Table 12.20 In this study, apart from free loureirin B, conjugated
metabolites of loureirin B such as sulfate and glucoside metabolites
were also detected in rat plasma samples, and the study suggests
the necessity of further detailed study of the metabolites.
3.2. Dioscorea nipponica (穿龍薯蕷 chuan long shǔ yù)
Protodioscin (3-O-[a l-rhamnopyranosyl-(1/2)-{a l-rhamno-
pyranosyl (1/4)}-b-D-glucopyranosyl]-26-O-[b-D-glucopyranosyl]-
(25R)-furost-5-ene-3b,26-diol) is a typical example of a furo-
stanol saponin, which is isolated from the roots of Dioscorea
nipponica Makino, and it also comprises Oriental vegetables and
medicinal plants. Protodioscin is found to be one of the potent
anticancer agents and in China its formulation is commercially
available.
HPLC-tandem MS with positive ion detection mode was used to
determine the pharmacokinetics of protodioscin after intravenous
administration in rats. The system was equipped with a Carbosorb
ODS-3 column (50  2.0mm i.d., 5 mm) and a security guard C18
guard column (4  2.0 mm i.d.) using a mobile phase of
acetonitrile-water-formic acid (80:20:0.1, v/v/v). The liquid ﬂow
rate and column temperature are 0.2 mL/min and 30C, respec-
tively. The LLOQ was found to be about 20.0 ng/mL. The pharma-
cokinetic parameters of protodioscin in rats after intravenous
administrations are provided in Table 13. The pharmacokinetic data
indicate that proportional increase in the area under the plasma
concentration-time curve with increasing protodioscin dose thus
conﬁrms the dose-dependent kinetic property.21
3.3. Flos Lonicerae (金銀花 jın yín hua)
Flos Lonicerae is one of the herbal plants reported in the litera-
ture about TCM. Various saponins are present in these plants,Table 12
Pharmacokinetic parameters of loureirin B after oral adminis-
tration of longxuejie (16 g/kg) to rats (n ¼ 6, mean ± standard
deviation.
Parameters Values
Kel (/h) 0.365 ± 0.06
t1/2 (h) 1.94 ± 0.27
T max (h) 0.81 ± 0.11
Cmax (mg/L) 7.99 ± 1.2
AUC0eT (mg h/L) 22.2 ± 1.9
AUC0e∞ (mg h/L) 22.6 ± 1.8
Cl (l/h/kg) 978.2 ± 117.3
Vc (l/kg) 2768.6 ± 751.5.
AUC ¼ area under the concentration-time curve; Cl ¼ clearance;
Cmax ¼ peak plasma concentration; Tmax ¼ time of peak plasma
concentration.which are useful in alleviating acute fever, headache, phar-
yngodynia, respiratory infection, pyocutaneous disease, and
epidemic disease and are also helpful in treating hepatic injury
caused by acetaminophen, Cd and CCl4, and conspicuous depres-
sant effects on swelling of ear croton oil.
A LC/MS with an ESI negative mode was used to determine the
pharmacokinetic parameters of four saponins after oral adminis-
tration. The system is equipped with an Agilent Zorbax C18 guard
column (12.5  4.6 mm i.d., 5 mm) and a Shim-Pack CLC-ODS col-
umn (150  6.0 mm i.d., 5.0 mm). The mobile phase was composed
of 0.2% acetic acid water (A) and acetonitrile (B) using a gradient
elution of 27e29% (v/v) B at 0e6 minutes; 29e33% B at 6e14 mi-
nutes; 33e50% B at 14e20 minutes; 50e80% B at 20e30 minutes.
The mobile phase ﬂow rate, injection volume, and column tem-
perature are 1.0 mL/min, 10 mL, and 25C, respectively. To maintain
the ﬂow rate of 0.25 mL/min and to avoid differences in nebuliza-
tion efﬁciency, a postcolumn split was used. The LOD and LOQ
(pooled plasma samples) values were 0.00234, 0.00184, 0.00217,
0.000433, and 0.00772, 0.00606, 0.00716, and 0.00143 mg/mL,
respectively. The pharmacokinetic parameters of the four saponins
after oral (2 g extract/kg) administration are presented in Table 14.
In this study double peaks were observed in both individual and
mean plasma concentration curves of the four saponins except for
macranthoside B. This type of diversity of pharmacokinetics of
various components is inﬂuenced by the complicated interactions
among compounds during the process of absorption, distribution,
metabolism and excretion.22
3.4. Forsythia suspense (Thunb) (連翹 lian qiao)
Forsythiaside, a phenylethanoid glycoside, is the most abundant
constituent in the fruit of Forsythia suspense (Thunb) Vahl. For-
sythiaside is able to show the antipyretic, antidote, and anti-
inﬂammatory properties in the treatment of various infections,
especially acute upper respiratory tract complaints caused by
viruses and/or bacterial infection.
A LC-MS/MS method was used to determine the pharmaco-
kinetic and oral bioavailability of forsythiaside in rats. The systemTable 14
Pharmacokinetic parameters of the four saponins after oral administration of 2 g
extraction/kg, each value represents the mean ± standard deviation (n ¼ 5).
Compound Cmax1 (mg/mL) Cmax2 (mg/mL) T max1 (h) T max2 (h) AUC0t
(mg/h/mL)
Macranthoidin B 1.39 1.30 5 18 22.79
Macranthoidin A 1.88 2.35 5 18 39.01
Dipsacoside B 1.73 2.20 5 18 39.62
Macranthoside B 0.10 0.64 e 18 19.52
AUC¼ area under the concentration-time curve; Cmax¼ peak plasma concentration;
Tmax ¼ time of peak plasma concentration.
Table 16
Pharmacokinetic parameters obtained by analyzing plasma samples after adminis-
tration of 10 mg/kg Flos Lonicerae extract to rabbits (n ¼ 4).
Parameters Values
AUC (mg min/mL) 140 ± 65.9
Area under ﬁrst moment curve (AUMC)
(mg min2/mL)
2.80  104 ± 1.73  104
MRT (min) 190 ± 38.3
Variance of the mean residence time (VRT)
(min.min)
1.28  104 ± 2.66  103
Kel (L/min) 0.0130 ± 0.0023
Tmax(min) 34.7 ± 1.09
Cmax (mg/mL) 0.839 ± 0.350
AUC¼ area under the concentration-time curve; Cmax¼ peak plasma concentration;
MRT ¼ mean residence time; Tmax ¼ time of peak plasma concentration;
Kel ¼ elimination rate constant.
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(250  4.6 mm i.d., 5 mm, San Jose, CA, USA), which was eluted
with a gradient mobile phase of acetonitrile (A) and water (B)
both containing 0.2% formic acid. The solvent A was 15% (v/v) at
the beginning and linearly increased to 35% over 7 minutes, and
then returned to 15% by 3 minutes. The mobile phase was deliv-
ered at a ﬂow rate of 1 mL/min and 40% of elute was introduced to
an Applied Biosystem 3200 Q-Trap mass spectrometer (Foster
City, CA, USA) with ESI source. The detection was performed by
negative ion ESI in multiple reaction monitoring mode. To
calculate the parameters in noncompartmental models and
plasma concentration versus time proﬁles, Win-Nonlin software
(Pharsight Corporation, Mountain View, CA, USA, (Version 2.1))
was used. The LOD and LOQ were 0.2 and 1.0 ng/mL, respectively,
when 100 mL of plasma was used for assay. The pharmacokinetic
parameters of forsythiaside in rats following intravenous and oral
administration are presented in Table 15. From pharmacokinetic
parameters it is clear that forsythiaside is rapidly absorbed into
the circulation system and reached its peak concentration at
around 20 minutes after oral administration but because of po-
tential hydrolysis in the gastrointestinal tract, poor permeability
through the intestinal epithelial membrane and ﬁrst-pass effect
in the liver might be responsible for the low bioavailability of the
compound.23
3.5. Flos Lonicerae: Flos Lonicerae (金銀花 jın yín hua)
Flos Lonicerae is one of several herbs present in TCM. It mainly
consists of a series of water-soluble phenolic components.
Chlorogenic acid is the main constituent of Flos Loniceae, which has
been reported to have activity of suppressing the N-nitrosating
reaction and inhibiting hepatic glucose 6-phosphatase.
A HPLC with UV detector was used to determine the pharma-
cokinetic parameters of Flos Lonicerae after administration of water
extract to rabbits. The system was equipped at room temperature
with an analytical column (MTPERSIL BDS C18, 250  4.6 mm i.d.,
5 mm). The mobile phase consisted of a mixture of acetonitrile-0.2%
H3PO4 (11:89, v/v) adjusted to pH 3.0 with sodium hydroxide
(0.2 g/mL). The ﬂow rate and method concentration range are
0.8 mL/min and 0.0500e1.00 mg/mL, respectively. The UV detector
was set at 327 nm. The LOQ was 0.0500 mg/mL. The pharmacoki-
netic parameters after administration of Flos Lonicerae water
extract to rabbits are presented in Table 16. After single-dose
administration of Flos Lonicerae extract, two maximum concen-
trations of chlorogenic acid were observed in rabbit plasma. The
study suggests the possible way of mechanism is by hepatoenteral
circulation.24Table 15
Pharmacokinetic parameters of forsythiaside in rats following intravenous (20 mg/
kg) and oral (100 mg/kg) administration.
Parameters The route of dosing
i.v. Oral
Cmax (ng/mL) e 122.2 ± 45.4
Tmax (min) 0.0 20.0 ± 0.0
Initial plasma concentration (C0) (mg/mL) 64.2 ± 36.1 e
t1/2, lz (min) terminal elimination half-life 76.8 ± 26.5 74.7 ± 13.3
AUC0et (mg min/mL) 570.5 ± 69.4 13.9 ± 5.2
AUC0e∞ (mg min/mL) 570.8 ± 69.2 14.6 ± 5.7
CL/F (mL/(min kg) 35.5 ± 4.2 39.4 ± 15.9
Volume of distribution (Vd), lz/F (L/kg) 4.0 ± 1.8 4.2 ± 1.9
Absolute bioavailability (F) (%) e 0.5
All data are expressed as mean ± standard deviation (n ¼ 5).
AUC¼ area under the concentration-time curve; Cmax¼ peak plasma concentration;
i.v. ¼ intravenous; Tmax ¼ time of peak plasma concentration; CL/F ¼ apparent
plasma clearance.3.6. Ginkgo biloba (銀杏 yín xìng)
Ginkgo biloba is a TCM herb mostly used to treat various
diseases. It contains mixtures of terpenoids and ﬂavonoids. The
ﬂavonoids, including ﬂavones (quercetin, kaempferol, and iso-
rhamnetin) and ﬂavonol glycosides are responsible for the free
radical scavenging effects of G. biloba, whereas the ginkgolides are
potent antiplatelet factor (PAF) antagonists. However, the oral
bioavailability of ﬂavonoids is relatively low because of their low
liposolubility and poor solubility, which severely limits their ability
to pass across the lipid-rich biological membranes, resulting in poor
bioavailability. In order to improve the absorption of ginkgo ﬂa-
vonoids in vivo, Ginkgo biloba extract (GBE), G. biloba extract
phospholipid complexes (GBP), and solid dispersions (GBS) are
formulated.
HPLC composed of an LC-20AB with SPDM20A (Shimadzu) was
used to determine the pharmacokinetic characteristics and
bioavailability of isorhamnetin, quercetin, and kaempferol after oral
administration of GBE, GBP, and GBS in rats. The system was
equipped with a Hedera ODS-2 column (250  4.6 mm i.d., particle
size 5 mm, Dalian Elite, China). The mobile phase composed of a
mixture of methanol and 0.4% phosphoric acid (60:40, v/v). The
ﬂow rate and column temperature are 1.0 mL/min and 35C,
respectively. The wavelength of UV detector was set at 360 nm.
Based on a signal-to-noise ratio (S/N ¼ 10), the LLOQ for iso-
rhamnetin, quercetin, and kaempferol were 0.039, 0.056, and
0.048 mg/mL, respectively. The main pharmacokinetic parameters
of isorhamnetin, quercetin, and kaempferol in rats are presented in
Tables 17, 18, and 19, respectively. In comparison with GBE, both
GBS and GBP showed better bioavailability, and the bioavailability
of GBP is more than that of GBS. The key parameter in G. biloba
ﬂavonoids is the modiﬁcation of liposolubility to enhance their
bioavailability.25Table 17
The main pharmacokinetic parameters of isorhamnetin in rats.
Parameter GBE GBP GBS
Ke (1/h) 0.0321 0.1135 0.0644
Absorption rate constant (Ka) (1/h) 0.2034 1.0512 0.6374
Tmax (h) 7.21 4.32 6.16
Cmax (ng/mL) 195.96 672.29 291.57
AUC (0~T) (ng/h/mL) 1153.66 2722.37 1738.889
MRT (0~T) (h) 6.3332 5.1331 5.3233
CL/F(s) (ng/h/(ng/mL)) 0.00022 0.00037 0.00041
AUC¼ area under the concentration-time curve; Cmax¼ peak plasma concentration;
GBE ¼ Ginkgo biloba extract; GBP ¼ G. biloba extract phospholipid complexes;
GBS ¼ G. biloba extract solid dispersions; MRT ¼mean residence time; Tmax ¼ time
of peak plasma concentration; CL/F ¼ Apparent clearance; Ke ¼ elimination rate
constant.
Table 18
The main pharmacokinetic parameters of quercetin in rats.
Parameter GBE GBP GBS
Ke (1/h) 0.0541 0.1909 0.1124
Ka (1/h) 0.6376 1.4162 1.3592
Tmax (h) 1.21 1.02 0.63
Cmax (ng/mL) 179.21 724.89 419.02
AUC (0~T) (ng/h/mL) 1368.26 3321.05 2841.63
MRT (0~T) (h) 5.4791 4.1442 4.6633
CL/F(s) (ng/h/(ng/mL)) 0.0015 0.0033 0.0038
AUC¼ area under the concentration-time curve; Cmax¼ peak plasma concentration;
GBE ¼ Ginkgo biloba extract; GBP ¼ G. biloba extract phospholipid complexes;
GBS ¼ G. biloba extract solid dispersions; MRT ¼mean residence time; Tmax ¼ time
of peak plasma concentration; CL/F ¼ Apparent clearance; Ke ¼ elimination rate
constant.
Table 19
The main pharmacokinetic parameters of kaempferol in rats.
Parameter GBE GBP GBS
Ke (1/h) 0.1641 0.3412 0.2875
Ka (1/h) 0.2029 0.8891 0.5570
Tmax (h) 6.32 5.83 1.33
Cmax (ng/mL) 180.23 323.56 280.54
AUC (0~T) (ng/h/mL) 1139.59 2228.21 1630.94
MRT (0~T) (h) 6.1712 5.5662 5.3033
CL/F(s) (ng/h/(ng/mL)) 0.0013 0.0028 0.0017
AUC¼ area under the concentration-time curve; Cmax¼ peak plasma concentration;
GBE ¼ Ginkgo biloba extract; GBP ¼ G. biloba extract phospholipid complexes;
GBS ¼ G. biloba extract solid dispersions; MRT ¼mean residence time; Tmax ¼ time
of peak plasma concentration; CL/F ¼ apparent clearance; Ka ¼ absorption rate
constant and Ke ¼ elimination rate constant.
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G. biloba extract is one of the known remedies for treatment of
various conditions. The standard ginkgo biloba extract, (EGb 761),
contains 22e27% ﬂavonoids and 5e7% lactones. Aglycones
comprise less than 0.1% in the extract. G. biloba extract is exten-
sively used therapeutically to increase peripheral and cerebral
blood ﬂow as well as for the treatment of dementia. G. biloba
extract was reported to show interactions with other drug cate-
gories such as antiplatelet, antidepressant, diuretic, and non-
steroidogenic anti-inﬂammatory drugs. In addition, it shows
signiﬁcant interaction with human cytochrome P450. Considering
consumer safety the kinetic behavior of the ﬂavonoids in vivo was
studied using the following method.
A HPLC with a diode-array detector was used to determine the
total ﬂavonoids in plasma after intravenous administration of
G. biloba. The systemwas equippedwith a C18 (4.6 150mm, 5 mm,
Waters) column with a guard C18 (4  15 mm i.d., 5 mm) column.
The mobile phase consisted of an acetonitrile-0.02 mol/L sodium
dihydrogen phosphate solution, containing 0.2% phosphoric acid,
pH-2.0, (35:65, V/V). The ﬂow rate, column temperature and
detection wavelength are 1.0 mL/min, 30C, and 360 nm respec-
tively. The injections are administered to 55 male Wistar rats at
doses of 50 mg/kg (containing 18 mg/mL ﬂavonoids) via the thigh
venae. Blood was collected from abdominal aorta by heparinized
needles and syringes after 15, 25, 30, 60, 90,120, 240, 360, 480, 600,
and 720 min of administration from ﬁve rats each time. Then the
blood was centrifuged at 3000 g for 15 minutes to obtain the
plasma samples, which are stored at 80C until assaying. The
detection limits are 20 ng/mL for quercetin, 20 ng/mL for kaemp-
ferol, and 50 ng/mL for isorhamnetin. The pharmacokinetic pa-
rameters are calculated using a two-compartment model. The
initial concentration in the plasma was 171.22 mg/mL. The half-life
of the ﬂavonoids in the ﬁrst compartment (distribution) the sec-
ond compartment (elimination) are 0.07 hours and 4.51 hours,respectively, whereas AUC0-∞, apparent volume of distribution and
total body clearance are found to be 1711.06 mg min/mL, 0.11 L/kg,
and 10.52 mL/(min.kg), respectively. The coingestion of 120 mg of
EGb 761 and 500 mg of metformin did not signiﬁcantly affect the
pharmacokinetic properties of metformin.26
3.8. Gardenia jasminoides (梔子花 zhı zǐ hua)
Geniposide is an iridoid glycoside extracted from the fruit of
Gardenia jasminoides. It is a well-knownTCM herbal plant. It is used
to treat disorders of the liver and gallbladder and also is known for
its antihyperbilirubinemic action. Long-term use of the Gardenia
extract and geniposide could induce hepatic pigmentation in pigs
and mice and produce a hepatotoxic effect, respectively.
A LC system was coupled with multiple microdialysis probes to
determine theamountofgeniposide in theblood, liver, brain, andbile
of anesthetized rats. The system was equipped with a Nova-Pak
(Waters, Milford, MA, USA) reverse-phase column RP-C18
(150  3.9 mm i.d.; 5 mm) at ambient temperature (24 ± 1 C). The
mobile phase consists of acetonitrile-methanol-5mM monosodium
phosphate (pH 4.6; 5:15:80, v/v/v), and the ﬂow rate of the mobile
phase was 1 mL/min. The maximum UV absorbance for geniposide
was set at a wavelength of 240 nm. Method helps to know the
pharmacokinetics of geniposide and its inﬂuence by the treatment of
acupuncture. The pharmacokinetic data on geniposide in rat blood
following geniposide administration are presented in Table 20. The
acupuncture does not affect the pharmacokinetics of the herbal
ingredient geniposide. However, several questions remain, and the
most important is, Do these results reveal the independent effects
between acupuncture and the pharmacokinetics of herbs?27
4. Homoeriodictyol-7-O-b-D-glucopyranoside
Homoeriodictyol-7-O-b-D-glucopyranoside (ﬂavone 40,5,7-
trihydroxy-30-methoxy-7-b-D-glucopyranoside, HEDT-Glu) iso-
lated from the TCM herb Viscum coloratum and Viscum album (槲寄
生 hú jì sheng). HEDT-Glu can inhibit platelet aggregation induced
by platelet-activating factor. Phytochemical investigations indi-
cated that Viscum coloratum helps to shows the inhibitory effect on
PAF and also the antioxidative activities.
A HPLC with UV detector was used to determine the pharma-
cokinetic parameters of HEDT-Glu (13.2 mg/kg) after intravenous
injection. The system was equipped with a Diamonsil C18 column
(200  4.6 mm i.d., 5 mm). A mobile phase consisted of methanol-
water-glacial acetic acid (45:55:0.5, v/v/v). The ﬂow rate, column
temperature, and UV detector wavelength are 1.0 mL/min, 30C,
and 284 nm, respectively. HEDT-Glu identiﬁcation was carried out
by MS (Finnigan TSQ), 1H- and 13C-NMR spectra (Bruker AVANCE-
300). The LOQ in plasma and tissue samples are 1 and 0.5 ng,
respectively. The main pharmacokinetic parameters of HEDT-Glu,
are presented in Table 21. Low levels of the HEDT-Glu remained
in the blood even 5 hours after intravenous administration. When s
cleared from the blood, it is distributed to the liver and small
intestine.28
4.1. Helicia nilagirica Bedd (山龍眼 shan long yǎn)
Helicid is themain chemical constituent extracted from the herb
Helicia nilagirica Bedd of TCM. It is used to treat neurasthenia,
neurasthenia syndrome, and vascular headache. From clinical
practice it was found that helicid has signiﬁcant healing effects,
with no side effects on patients.
LC-ESI-MS method with negative ionization mode was used for
identiﬁcation and quantiﬁcation of helicid in rat plasma. The
pharmacokinetic parameters are also determined in rats after
Table 20
Estimated pharmacokinetic data on geniposide in rat blood following geniposide administration (10, 30, and 100 mg kg1, intravenously).
Parameters Geniposide 10 mg/kg1 Geniposide 30 mg/kg1 Geniposide 100 mg/kg1
With out acupuncture With acupuncture Without acupuncture With acupuncture Without acupuncture With acupuncture
A. Blood
AUC (min mgml1) 417 ± 17 486 ± 59 1102 ± 32 1235 ± 128 4759 ± 601 4233 ± 411
MRT (min) 15 ± 1 15 ± 1 18 ± 1 17 ± 2 17 ± 2 17 ± 2
Cl (ml min1 kg1) 24 ± 1 22 ± 2 27 ± 1 26 ± 3 23 ± 3 25 ± 2
B. Liver
AUC (min mgml1) 550 ± 107 637 ± 76 e e e e
MRT (min) 16 ± 2 19 ± 3 e e e e
C. Bile
AUC (min mgml1) 1039 ± 136 1001 ± 90 e e e e
MRT (min) 37 ± 2 39 ± 1 e e e e
AUC liver/AUC blood 1.34 ± 0.27 1.41 ± 0.24 e e e e
AUC bile/AUC blood 2.50 ± 0.33 2.10 ± 0.10 e e e e
Data are expressed as mean ± standard error of the mean from six individual micro-dialysis experiments at each dose treatment.
AUC ¼ area under the concentration-time curve; Cl ¼ clearance; MRT ¼ mean residence time.
Table 21
Pharmacokinetic parameters of HEDT-Glu Following after intravenous administra-
tion 13.2 mg$kg1 HEDT-Glu in rats (n ¼ 6).
Parameters Values
AUC 16.04 ± 3.19 m g$h$mL1.
Elimination half-life at the a phases (t1/2,a) 0.06 ± 0.01 h
Elimination half-life at the b phase (t1/2,b) phases 1.27 ± 0.31 h
Ke 9.78 ± 1.61 h1
CL 0.85 ± 0.17 l$kg1$h1.
AUC ¼ area under the concentration-time curve; CL ¼ clearance; Ke ¼ elimination
rate constant.
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The systemwas equipped with a Luna C18 column (150  2.00 mm
i.d., 5 mm). A mobile phase composed of acetonitrile-0.1% ammonia
solution (20:80, v/v) at a ﬂow rate of 0.3 mL/min. The LLOQ was
found to be 1 mg/L. The pharmacokinetic parameters of helicid after
oral administration are presented in Table 22. The plasma con-
centration of helicid was much lower in humans in comparison
with rats and dogs, which suggests the existence of species differ-
ences but there is no signiﬁcant species difference between human
and rats for the plasma protein binding of helicid.29
5. Hawthorn (山楂 shan zha)
Hawthorn (Crataegus) is widely used as a medicinal plant in folk
and ofﬁcial medicine. There are about 16 species in China, where
Crataegus Pinnatiﬁda Bge. Var Major N. E. Br, and Crataegus Pinna-
tiﬁda Bge. (山裏紅果 shan lǐ hong guǒ) are the two major species,
named as Shanlihong and Shanzha, respectively. Hawthorn leaves
ﬂavonoids (HLF) include many types of ﬂavonoids, e.g., vitexin-400-
O-glucoside (VGL), vitexin-200-O-rhamnoside (VRH), vitexin,
vitexin-600-O-acetyl, rutin, hyperoside, quercitrin, and quercetin.Table 22
Pharmacokinetic parameter of helicid after oral administration of a single dose of
100 mg.
Parameter Values
Cmax (m g/L) 10.6 ± 3.11
Tmax (h) 1.08 ± 0.47
t1/2 (h) 5.27 ± 0.89
AUC024 (m g h/L) 37.25 ± 5.33
AUC0∞ (m g h/L) 40.34 ± 6.04
F (%) 48.34 in rats and 22.85 in dogs
AUC ¼ area under the concentration-time curve; Cmax ¼ peak plasma concen-
tration; Tmax ¼ time of peak plasma concentration; t1/2 ¼ half life; F ¼ absolute
bioavailability.The HPLC with UV detector was used to determine the phar-
macokinetic parameters of HLF. The system was equipped with
reverse-phase Diamonsil TM C18 (200  4.6 mm i.d., 5 mm) column
in presence of a guard column (Easy Guard C18 Kit, 8  4 mm,
Dikma Technologies Inc.). The mobile phase composed of
methanol-acetonitrile-tetrahydrofuran-0.5% acetic acid
(1:1:19.4:78.6, v/v/v/v). The ﬂow rate, column temperature, and UV
detection are 0.8 mL/min, 30C, and 330 nm, respectively. The
sample injection and plasma required for both compounds are
20 mL and 100 mL, respectively. The LOQs are 0.23 mg/mL for VGL and
0.36 mg/mL for VRH and the relative standard deviations (RSDs) for
both compounds are less than 20%. The pharmacokinetic parame-
ters and dose-linear pharmacokinetics are carried out by
compartmental, statistical moment (i.e., noncompartmental)
analysis and least squares regression analysis, respectively. With
minimum AIC values, a three-compartment open pharmacokinetic
model was proposed and validated through the DAS 2.0.1. The
pharmacokinetic parameters for VGL and VRH after a single intra-
venous administration of HLF are provided in Table 23. From the
results it is found that the plasma concentrations and AUC of VGL
and VRH in rat plasma were proportional to the administrated
doses.305.1. Huperzia serrata (Thumb) (千層塔 qian ceng tǎ)
Huperzia serrata (Thumb.) Trev. is awell-knownTCMplant used to
relieve contusions, strains, and swelling, and to treat schizophrenia.
As the peripheral cholinergic effect are often observed as the main
side effect for this herb in clinic practice, it was suggested that the
active component fromH. serratamight be studied as a newdrug for
the treatment of neurodegenerative disorder such as Alzheimer
disease. Bis(12)-hupyridone (B12H), a homodimer by linking two
hupyridone fragments derived fromHupA, is a promising candidate
for acetylcholinesterase (AChE) inhibition. In addition, as a more
potent and selective anti-AChE agent, chemically synthesized B12H
can be more easily prepared for its further commercialization and
clinical use.
A HPLC DAD systemwas used to determine the pharmacokinetic
proﬁles of B12H after intravenous (5 mg/kg and 10mg/kg) and intra
peritoneal (20 mg/kg) administration to rats. The system was
equipped with an Agilent Extend C-18 analytical column
(250 4.6mm i.d., 5 mm) and protectedwith an Agilent Extend C-18
guard-column (12.5  4.6 mm i.d., 5 mm) maintained at 25C. The
iso-cratical elution with a mobile phase of water-ACN-
triﬂuoroacetic acid (TFA) (81:19:0.04, v/v/v) was used at a ﬂow
rate of 1.0mL/min for the separation of analytes. The UV detector
Table 23
Pharmacokinetic parameters for VGL and VRH in SD rats (mean ± standard deviation, n ¼ 6) after a single intravenous administration of Hawthorn leaves ﬂavonoids.
Pharmacokinetic parameter VGL VRH
0.61 mg/kg 1.22 mg/kg 2.45 mg/kg 1.40 mg/kg 2.80 mg/kg 5.60 mg/kg
t1/2 a (h) 0.028 ± 0.002 0.029 ± 0.006 0.031 ± 0.003 0.029 ± 0.002 0.03 ± 0.005 0.033 ± 0.004
t1/2 b (h) 0.251 ± 0.004 0.25 ± 0.037 0.265 ± 0.006 0.25 ± 0.01 0.246 ± 0.035 0.26 ± 0.006
Half-life of elimination phase (t1/2 g) (h) 2.671 ± 0.087 2.416 ± 0.137 2.373 ± 0.068 2.325 ± 0.163 2.273 ± 0.095 2.176 ± 0.051
Apparent volumes of distribution of the central compartments
(V1) (L/kg)
0.021 ± 0.004 0.024 ± 0.01 0.024 ± 0.005 0.020 ± 0.006 0.022 ± 0.008 0.022 ± 0.003
CL (L/h/kg) 0.096 ± 0.013 0.101 ± 0.014 0.097 ± 0.010 0.094 ± 0.01 0.0932 ± 0.013 0.089 ± 0.01
AUC(0t) (mg h/L) 4.492 ± 0.54 9.337 ± 1.215 20.891 ± 2.489 10.892 ± 1.168 23.766 ± 3.447 51.71 ± 6.504
AUC(0∞) (mg h/L) 5.60 ± 0.778 10.578 ± 1.507 21.605 ± 2.459 12.664 ± 1.387 26.324 ± 4.238 53.984 ± 6.615
MRT(0t) (h) 1.268 ± 0. 1.478 ± 0.032 1.73 ± 0.018 1.212 ± 0.016 1.45 ± 0.05 1.668 ± 0.012
MRT(0∞) (h) 2.543 ± 0.225 013 2.269 ± 0.096 2.18 ± 0.054 2.123 ± 0.215 2.142 ± 0.108 2.11 ± 0.071
AUC ¼ area under the concentration-time curve; MRT ¼ mean residence time.
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calculated with a two-compartmental and/or noncompartmental
approach. The LOD and LOQ of this method are 0.05 mg/mL and
0.1 mg/mL, respectively. The pharmacokinetic parameters are pre-
sented in Table 24. The pharmacokinetic data indicated that after
extravascular injection B12H could be well absorbed and most of
the administered drug could enter into the systemic circulation.31
5.2. Isodon rubescens (Hemsl.) (冬凌草 dong líng cǎo)
Isodon rubescens (Hemsl.) Hara (Labiatae) is a perennial herb,
native to China. It is one of the folk remedies for respiratory and
gastrointestinal bacterial infections, inﬂammation, and cancer. The
different diterpenoids found in the plants are lasiodonin, oridonin,
ponicidin, and rabdoternin A. These compounds are able to shows a
variety of biological actions such as antitumor, antimicrobial, anti-
inﬂammatory, anticatastrophe, and antioxidation effects.
HPLC-ESI-MS method with positive ionization mode was used
to determine pharmacokinetic proﬁles four diterpenoids in rat
plasma after the single oral administration of I. rubescens ethanolic
extract. The system was equipped with a Diamonsil C18
(250  4.6 mm i.d., 5 mm) column. The mass spectrometer was
operated in the chemical determination process, whichwas divided
into three periods. A linear gradient elution of methanol containing
0.1% formic acid (A) and 0.1% [v/v] aqueous formic acid (B) was used
for the separation. The solvent ﬂow, column temperature, and total
run time between injections are 0.8 mL/min, 25C, and 13.5Table 24
Pharmacokinetic parameters were calculated with two-compartmental and/or
noncompartmental approach. Absolute bioavailability (F) was calculated as the ratio
of the dose-normalized AUC0/∞ after i.p. injection (10 or 20 mg/kg) to that after
bolus intravenous injection (5 mg/kg) of B12H.
Pharmacokinetic
parameters
Route of administration
Intravenous Intraperitoneal
5 mg/kg 10 mg/kg 20 mg/kg
L z (L/min) 0.0050 ± 0.0005 0.0045 ± 0.0009 0.0059 ± 0.0008
AUC0/t (min mg/mL) 62.62 ± 5.47 96.15 ± 20.67 219.92 ± 8.78
AUC0/∞ (min mg/mL) 82.50 ± 8.55 125.73 ± 28.92 266.12 ± 13.14
MRT (h) 2.67 ± 0.18 3.84 ± 0.37 3.14 ± 0.37
Cmax (mg/mL) e 0.93 ± 0.23 1.91 ± 0.29
tmax (min) e 9.33 ± 6.25 4.75 ± 2.36
t1/2 (h) 2.35 ± 0.29 2.63 ± 0.49 1.99 ± 0.29
CL (L/(min kg)) 0.061 ± 0.006 0.055 ± 0.016 0.093 ± 0.005
Vd (L/kg) 12.35 ± 1.24 12.09 ± 1.72 16.06 ± 1.86
F (%) e 76.2 80.7
AUC ¼ area under the concentration-time curve; MRT ¼ mean residence time;
Cmax ¼ maximum blood concentration; tmax ¼ time to peak concentration;
t1/2 ¼ elimination half-life; Vd ¼ the volume of distribution; CL ¼ total blood
clearance; F ¼ absolute bioavailability.minutes, respectively. Over the range from 0.0 to 10.5 min, lasio-
donin, oridonin, and Internal Standards are easily detected. The
pharmacokinetic parameters of the four diterpenoids after single
oral administration of I. rubescens ethanolic extract are presented in
Tables 25 and 26. All four diterpenoids shows good absorptionwith
oral administration. They are easily detected in plasma after 10
minutes and eliminated quickly at a similar rate.32
5.3. Isatis indigotica L. (菘藍 song lan)
Indolinone [(E,Z)-3-(4-hydroxy-3,5-dimethoxybenzylidene)
indolin-2-one], is an alkaloid present in the TCM different herbs. It
is present in the dried roots of I. indigotica L. (Brassicaceae) (板藍根
bǎn lan gen) and in leaves of I. tinctoria L (European woad) (板藍葉
bǎn lan ye). Indolinone is useful in the inhibition of mast cell
degranulation as well as block immunoglobulin E (IgE) mediated
degranulation of sensitized mast cells.
An UPLC-MS/MS method with positive ionization mode was
used to determine the pharmacokinetic parameters after a single
intravenous of indolinone in rats. The system was equipped with a
Waters UPLC HSS T3 column (100  2.1 mm i.d., 1.8 mm) protected
by an Acquity UPLC column in-line ﬁlter unit (0.2 mm in-line frit).
Seal wash solvent was water-acetonitrile (70:30, v/v), weak and
strong wash solvents was water-acetonitrile (50:50, v/v; containing
0.2% TFA) and acetonitrile-isopropanol-acetone (40:30:30, v/v/v;
containing 0.2% TFA), respectively. The ﬂow rate was set as 0.5 mL/
min. The standard calibration curve of indolinone generated be-
tween 30.0 and 3000 ng/mL was found to be quadratic. The LOQ
was found to be 30.0 ng/mL. Indolinone was found to be stable in
rat plasma samples kept for 4 hours on the bench at room tem-
perature, after three successive freeze/thaw cycles, and in pro-
cessed plasma samples stored at circa 10C for 4 days. The main
pharmacokinetic parameters of indolinone calculated by non-
compartmental analysis using Win-Nonlin software. The pharma-
cokinetic parameters after a single intravenous of indolinone in rats
are presented in Table 27. The pharmacokinetic data indicate short
half-life and a relatively high clearance.33
5.4. Mangifera indica (檬果 meng guǒ)
Mangiferin (1,3,6,7-tetrahydroxyxanthone-C-2-b-D-glucoside)
is a natural glucosyl obtained from the TCM herb, Mangifera indica.
Recently, it is found that mangiferin is a promising agent for oral
diabetes treatment.
An ACQUITYTM UPLC/MS system (Waters Corp., Milford, MA,
USA) at 4C was used to determine the pharmacokinetic parame-
ters of mangiferin after oral and intravenous administration. The
mass spectrometer was equipped with TQD triple-quadrupole
tandem mass spectrometer in positive ESI mode. The system was
Table 25
Pharmacokinetic parameters of the four diterpenoids in six rats plasma after single oral administration of I. rubescens extract 10 mL/kg (n ¼ 6).
Pharmacokinetic parameter Compound
Lasiodonin Oridonin Ponicidin Rabdoternin A
Cmax (ng/mL) (means ± SD) 1300.717 ± 365.53 1916.333 ± 307.20 1582.383 ± 307.20 385.011 ± 58.35
Tmax (min) 105 105 120 105
t1/2 (min) (means ± SD) 40.984 ± 9.12 45.147 ± 11.42 40.269 ± 9.05 58.04 ± 12.02
K (1/min) (means ± SD) 0.0177 ± 0.0045 0.0161 ± 0.0037 0.0179 ± 0.0035 0.0124 ± 0.0024
AUC0et (ng/min/mL) (means ± SD) 96990.82 ± 26493.23 142768.30 ± 34344.80 115004.70 ± 15237.04 28958.63 ± 5530.37
AUC0e1 (ng/min/mL)
(means ± SD)
97916.68 ± 5348.35 144527.30 ± 33606.69 116425.80 ± 15969.54 29522.15 ± 5348.35
AUC ¼ area under the concentration-time curve; SD ¼ standard deviation; Cmax ¼ maximum blood concentration; Tmax ¼ time to peak concentration; t1/2 ¼ half-life.
Table 26
Lower limit of quantiﬁcation and limit of detection for given diterpenoids
compounds.
Compound LLOQ (ng/mL) LOD (ng/mL)
Lasiodonin 2.24 0.540
Oridonin 4.92 0.826
Ponicidin 5.32 0.736
Rabdotemin A 1.36 0.432
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i.d., 1.7 mm), which is set at 35C. Gradient elution of acetonitrile (A)
and water containing 0.1% formic acid (B) is used as a mobile phase.
The elution started with 90% B then the composition was linearly
changed to 30% B over 0.5 minutes and maintained at the level for
1.4 minutes. Finally, the composition was returned to the initial
composition over 0.1 minutes and maintained for 1.0 min. The oral
bioavailability was found to be 1.2%. The LLOQ (0.02 and 0.4 mg/mL)
was deﬁned as the lowest concentration on the calibration curves.
The pharmacokinetic parameters are calculated applying a non-
compartmental model. The pharmacokinetic parameters of man-
giferin after oral and intravenous administration to rats areTable 27
Pharmacokinetic parameters after a single intravenous dose of 2 mg/kg indolinone
in rats (n ¼ 4).
Parameters Mean SE
C0 (ng/mL) 5205 2232
t1/2 (min) 4.30 0.14
Ke (1/h) 9.53 0.21
AUC0elast (ng h/mL) 561 166
AUC0e∞ (ng h/mL) 568 162
MRT (min) 5.16 0.59
Vz (L/kg) 0.39 0.15
CL (L/h/kg) 3.38 1.46
Data were calculated using noncompartmental analysis.
AUC ¼ area under the concentration-time curve; MRT ¼ mean residence time;
SE ¼ standard error; C0 ¼ Initial plasma concentration; t1/2 ¼ half-life; CL ¼ total
blood clearance and Ke ¼ elimination rate constant.
Table 28
Pharmacokinetic parameters of mangiferin after oral and intravenous administra-
tion to rats.
Parameter Oral administration
(n ¼ 6)
Intravenous administration
(n ¼ 6)
AUC(0et) (mg/L h) 1855.0 ± 887.7 61184.1 ± 22471.4
AUC(0e∞) (mg/L h) 2036.2 ± 942.2 62065.2 ± 23013.2
T1/2 (h) 3.2 ± 0.6 0.9 ± 0.4
Tmax (h) 2.5 ± 0.8 0.083
MRT0et (h) 4.3 ± 0.5 1.3 ± 0.2
Cmax (mg/L) 301.3 ± 133.0 67798.3 ± 31235.9
CLz (L/h kg) (13.95 ± 4.64)  F 0.15 ± 0.04
AUC¼ area under the concentration-time curve; Cmaxe peak plasma concentration;
MRT ¼ mean residence time; Tmax ¼ time of peak plasma concentration.presented in Table 28. The oral bioavailability of mangiferin was
found to be 1.2%. To improve the oral bioavailability of mangiferin
chemical and pharmaceutical modiﬁcation may be useful.34
5.5. Pueraria lobata (Willd) (大葛藤 da ge teng)
Kakkalide (KA) is themajor isoﬂavone found in extracts from the
dried ﬂower of Pueraria lobata (Willd.). It is one of the TCM herbal
remedies for symptoms associated with excessive alcohol intake,
such as drunkenness, headache, red face, and liver injury. Three
known glucuronide metabolites are irisolidone-7-O-glucuronide
(Ir-7G), tectorigenin-7-O-glucuronide (Te-7G), and 6-OH biochanin
A-glucuronide (6-OH BiA-G). A LC-MS/MS was used to determine
the pharmacokinetic parameters for KA and its metabolites in rat
plasma. LC/MSD (Agilent 1100 Series) Trap was operated at nega-
tive ESI interface. The system was equipped with a Kromasil
(Tianjin Scientiﬁc Instruments Co. Ltd., China) C18 column
(4.6  200 mm i.d., 5 mm) at 35C. The mobile phase was composed
of acetonitrile containing 0.05% TFA (A) and water containing 0.05%
TFA (B), eluted in a gradient way. For the identiﬁcation of irisoli-
done, the mobile phase consisting of solutions A and B was run in
isocratic mode in the ratio of 44:56 (v/v). The ﬂow rate was 1.0 mL/
min. The injection volume and detection wavelength are 20 mL and
265 nm, respectively. Pharmacokinetic parameters are determined
by using noncompartmental analysis. The pharmacokinetic pa-
rameters for KA and its metabolites in rat plasma are presented in
Table 29. After oral administration of KA in rats, Phase II meta-
bolism occurs and it forms 13 different metabolites that are found
in rat urine, in which irisolidone (Ir), tectorigenin (Te), irisolidone-
7-O-glucuronide (Ir-7G), tectorigenin-7-O-sulfate (Te-7S), and tec-
torigenin-40-O-sulfate (Te-40S) were characterized. The AUC0t
values of the glucuronide metabolites are signiﬁcantly greater than
that of KA. KA metabolism in vivo may occur in different sites, ﬁrstTable 29
Pharmacokinetic parameters for kakkalide (oral 200 mg/kg1) and its metabolites in
rat plasma.
Parameters KA Ir-7G Te-7G 6-OH BiA-G
Tmax (h) 0.25 ± 0.00 34.0 ± 11.8 38.0 ± 9.0 36.0 ± 7.6
Cmax (mg/mL) 0.26 ± 0.17 2.73 ± 0.74 0.55 ± 0.22 2.33 ± 1.29
AUC(0t)
(mg$h/mL)
0.24 ± 0.16 65.2 ± 11.7 17.0 ± 4.7 54.9 ± 26.7
AUC(0∞)
(mg$h/mL)
0.25 ± 0.16 104.3 ± 38.2 27.2 ± 13.9 56.7 ± 25.7
t1/2 (h) 0.95 ± 0.52 e e e
MRT(0t) (h) 1.22 ± 0.58 31.3 ± 6.0 40.5 ± 4.1 37.1 ± 4.6
MRT(0∞) (h) 1.55 ± 0.72 46.1 ± 13.6 102 .3 ± 125.1 40.1 ± 6.4
CLz/F (L/h/kg) 1021.7 ± 486.5 2.18 ± 0.93 8.46 ± 2.81 4.21 ± 1.95
Vz/F (L/kg) 1388.3 ± 1061.0 55.6 ± 33.4 472.9 ± 442.0 91.0 ± 120.4
AUC¼ area under the concentration-time curve; Cmax¼ peak plasma concentration;
MRT ¼ mean residence time; Tmax ¼ time of peak plasma concentration; CL/
F ¼ apparent plasma clearance; t1/2 ¼ half life.
Table 30
Pharmacokinetic parameters for metabolites in rat plasma after oral administration
of 200 mg/kg tectoridin.
Parameters Te-7G-40S Te-7G Te-7S Tectorigenin
Tmax (h) 3.50 ± 1.87 3.17 ± 1.81 5.58 ± 3.07 4.92 ± 2.87
Cmax (mmol/L) 21.4 ± 13.8 20.5 ± 9.70 14.3 ± 3.30 8.67 ± 3.07
AUC(0et) (mmol/L) 164 ± 52 184 ± 73 123 ± 63 72.0 ± 22.0
AUC(0e∞) (mmol/L) 197 ± 79 198 ± 78 199 ± 91 98.0 ± 47.7
MRT(0et) (h) 9.79 ± 4.47 10.7 ± 4.30 8.12 ± 3.37 8.54 ± 2.01
MRT(0e∞) (h) 20.4 ± 16.7 13.7 ± 6.00 15.9 ± 7.12 12.5 ± 3.90
CL/F (L/h/kg) 2.13 ± 0.96 2.35 ± 0.76 3.28 ± 1.85 8.13 ± 3.57
V/F (L/kg) 31.3 ± 13.8 31.0 ± 23.1 37.9 ± 20.9 80.7 ± 33.1
Data are mean ± standard deviation (n ¼ 6).
AUC¼ area under the concentration-time curve; Cmax¼ peak plasma concentration;
MRT ¼ mean residence time; Tmax ¼ time of peak plasma concentration; CL/
F ¼ apparent plasma clearance.
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recirculation prolongs the elimination of these glucuronide
metabolites.35
5.6. Pueraria thomsonii (大葛藤 da ge teng)
The isoﬂavone tectoridin is present in large quantities in the
ﬂowers of Pueraria thomsonii Benth, a TCM plant. It is useful in the
treatment of various disorders such as diabetes, and excessive
alcohol intake disorders such as drunkenness, headache, red face,
and liver injury. Tectoridin possesses hepatoprotective, estrogenic,
antihypolipidemic, antioxidative, and anti-inﬂammatory proper-
ties. The various metabolites of tectoridin are tectorigenin-
7-Oglucuronide- 40-O-sulfate (Te-7G-40S), Te-7G-40S, tectorigenin-
7-Oglucuronide (Te-7G), and tectorigenin-7-O-sulfate (Te-7S).
A HPLC with UV detector was used to quantitatively determine
the pharmacokinetic parameters of four tectoridin metabolites in
rat plasma. The system was equipped with Kromasil C18 column
(4.6  200 mm, 5 mm). The mobile phase comprising a gradient
system of acetonitrile (A) and water containing 0.1% formic acid
(B) at a ﬂow rate of 0.8 mL/min at 35 C as follows: a linear
gradient of the mixture of solutions (A:B) from 12:88 (v/v) to 17:83
for 10 minutes, then maintained at 17:83 for 8 minutes, followed
by a linear gradient of solutions (A:B) from 17:83 to 24:76 for 9
minutes, maintained at 24:76 for 5 minutes, and ﬁnally a linear
gradient of solutions (A:B) from 24:76 to 50:50 for 28 minutes. The
injection volume was 10 mL. To determine the metabolites, a mo-
bile phase comprising a gradient system of acetonitrile containing
0.05% TFA (A) and water containing 0.05% TFA (B) at a ﬂow rate of
0.8 mL/min as follows: a linear gradient of the mixture of solutions
(A:B) from 14:86 to 20:80 for 19 minutes, followed by a linearTable 31
Pharmacokinetic parameters of paeonol in rat plasma after single oral administration of
Parameters Paeonol
35 mg/kg 70 mg/k
Cmax (mg/mL) 0.73 ± 0.07 2.02
Tmax (min) 9.00 ± 2.45 5.00
T1/2 E phase (min) 34.25 ± 3.91 34.18
T1/2 D/A phase (min) 12.02 ± 1.73 12.74
T1/2 A phase (min) 2.60 ± 0.53 1.92
MRT (min) 51.62 ± 8.86 36.65
Vd (ml/kg) 47,170 ± 5984 49,628
CL/F (ml/(min kg)) 1016.8 ± 167.7 1003.4
AUC0t (mg min/mL) 40.66 ± 9.99 74.13
AUC 0∞ (mg min/mL) 40.72 ± 10.01 74.38
Data are expressed as the mean ± standard error of the mean of 6 to 8 rats. Paeonol contai
signiﬁcantly different from that of the paeonol alone (at a dosage of 70 mg/kg) group by
AUC ¼ area under the concentration-time curve; Cmax ¼ peak plasma concentration; MR
concentration; CL/F ¼ apparent plasma clearance; Vd ¼ volume of distribution; T1/2 ¼ hgradient from 20:80 to 27:73 for 9 minutes, and from 27:73 to
42:58 for 19 minutes. The injection volume and detection wave-
length are 20 mL and 264 nm, respectively. LLOQs and those for Te-
7G, Te-7S and tectorigenin, and tectoridin are found to be 125,
200, 25, and 150 ng/mL, respectively. The pharmacokinetic pa-
rameters for tectoridin (200 mg/kg) metabolites in rat plasma after
oral administration are presented in Table 30. The plasma con-
centrations of tectorigenin conjugated metabolites were higher
than those of the tectorigenin aglycone, as it undergoes Phase II
metabolism and forms glucuronide and sulfate conjugates, and a
glucuronidesulfate bisconjugate. These conjugates also undergo
enterohepatic recirculation. The extensive Phase II metabolism
plays an important role in the pharmacokinetics of tectoridin and
tectorigenin in vivo.36
5.7. Paeonia suffruticosa (牡丹 mǔ dan)
Paeonol (20-hydroxy-40-methoxyacetophenone) is a major
component in the medicinal herb Moutan Cortex, the root cortex of
Paeonia suffruticosa A. (Paeoniaceae) (牡丹皮 mǔ dan pí). It is
commonly prescribed for the treatment of pain and inﬂammatory
ailments in Chinese medicine.
A HPLC-DAD method was used to determine pharmacokinetic
proﬁling of pure paeonol including its metabolites and herbal
preparation. The system was equipped with a Phenomenex ODS
(250  4.6 mm i.d., 5 mm, Phenomenex Inc., USA) protected by a
Security Guard Cartridge (C18, 4.0 3.0 mm i.d.; Phenomenex Inc.).
The mobile phase composed of acetonitrile (A) and aqueous solu-
tion containing 0.1% formic acid (B) (pH adjusted to 3.5 ± 0.2 by
triethylamine). At normal room temperature ﬂow rate, injection
volumes and wavelength for detection are 1.0 mL/min, 50 mL, and
270 nm, respectively. The LLOQ in rat plasma was found to be
0.15 mg/mL of paeonol. Pharmacokinetic parameters are calculated
based on the noncompartment method. The pharmacokinetic pa-
rameters of paeonol in rat plasma after single oral administration of
paeonol alone and paeonol contained in the herbal preparation
Qingfu Guanjieshu (QFGJS) are presented in Table 31. After oral
administration of paeonol and QFGJS in rats, ﬁve metabolites of
paeonol, P1eP5, were identiﬁed in rat urine. The relative plasma
concentration of these metabolites was found to be signiﬁcantly
higher in rats treated with QFGJS than those treated with pure
paeonol at a comparable dose. Four metabolites, P2eP5, appeared
as soon as 5 minutes after dosing and reached the maximum
plasma concentrations in approximately 20 minutes. This study
indicating that paeonol could quickly be metabolized into P2eP5
and circulate in the blood and/or the tissues and organs, but
metabolite P1 is not found in plasma.37paeonol alone and paeonol contained in the herbal preparation Qingfu Guanjieshu.
QFGJS
g 140 mg/kg 3.89 g/kg
± 0.23 4.16 ± 0.50 8.61 ± 1.30**
± 0.00 7.00 ± 2.00 5.00 ± 0.00
± 1.77 50.13 ± 4.11 38.25 ± 2.99
± 1.69 12.79 ± 1.81 11.66 ± 0.62
± 0.44 2.51 ± 0.38 1.58 ± 0.21
± 2.18 56.14 ± 3.13 37.43 ± 2.58
± 6810 48,329 ± 6424 18,034 ± 1498*
± 110.5 761.0 ± 70.6 342.2 ± 39.8***
± 8.68 188.50 ± 16.35 229.64 ± 27.38**
± 8.77 189.22 ± 16.47 229.88 ± 27.46**
ned in QFGJS at dosage of 3.89 g/kg is equivalent to 70 mg/kg pure paeonol to rat. p is
Student t test. *p < 0.05; **p < 0.01; ***p < 0.001.
T ¼ mean residence time; QFGJS ¼ Qingfu Guanjieshu; Tmax ¼ time of peak plasma
alf life.
Table 33
Mean pharmacokinetic parameters of three alkaloids after oral administration of
Rhizoma Corydalis Decumbentis extract at 2.0 g kg1 to rats (n ¼ 6).
Parameter Tetrahydropalmatine Protopine Palmatine
t1/2 (h) 6.68 ± 0.64 4.98 ± 1.64 12.84 ± 4.58
Tmax (h) 1.50 ± 1.14 3.50 ± 0.55 1.92 ± 0.74
Cmax (ng/mL1) 435.8 ± 58.5 347.9 ± 51.51 8.53 ± 2.95
MRT(0t) (h) 7.21 ± 0.21 7.36 ± 0.64 8.10 ± 1.07
MRT(0∞) (h) 9.32 ± 0.58 8.84 ± 1.88 16.89 ± 6.27
AUC(0t) (ng/h/mL1) 3450.1 ± 480.9 2987.0 ± 354.0 57.85 ± 13.44
AUC(0∞) (ng/h/mL1) 3720.1 ± 498.3 3150.8 ± 482.8 77.58 ± 27.01
AUC¼ area under the concentration-time curve; Cmax¼ peak plasma concentration;
MRT ¼mean residence time; Tmax ¼ time of peak plasma concentration; t1/2 ¼ half
life.
Table 34
Pharmacokinetic parameter of rhein.
Administration
route
Parameters RE REM REE
i.g. Tmax (h) 0.9 ± 0.1 6.7 ± 2.3* 10.7 ± 2.3**
Cmax (mg/L) 42.66 ± 14.41 0.058 ± 0.035** 0.95 ± 0.090**
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Pulsatilla koreana Nakai (Ranunculaceae) is a traditional Korean
herbal medicine used to treat amoebic dysentery and malaria.
A standardized extract of P. koreana, SK-PC-B70M, improves
scopolamine-induced impairments of memory consolidation and
spatial working memory. Oleanolic-glycoside saponins, especially
hederacolchiside E, are not only the major constituents but also the
marker compounds for the SK-PC-B70M. Hederacolchiside E is an
essential saponin that helps facilitate detailed pharmacokinetic study
and also future preclinical or clinical investigation of SK-PC-B70M.
A LC-MS/MS with negative EIS was used to determine phar-
macokinetic parameters of hederacolchiside E after oral adminis-
tration. The system was equipped with a Hydrosphere C18 column
(2.0  50 mm i.d., 3 mm; YMC Co., Ltd., Kyoto, Japan). Nitrogen
(99.999%) was used as the nebulizing turbo spray and curtain gas,
with the optimum values set at 60, 60, and 20 (arbitrary units),
respectively. The HPLC mobile phases consisted of 0.1% formic acid:
tetrahydrofuran (FA:THF) (90:10) (A) and acetonitrile:0.1% FA:THF
(80:10:10) (B). A linear gradient programwas usedwith ﬂow rate of
0.5 mL/min. Solvent (B) was gradually increased 60% for 3 minutes,
maintained for 0.5 minutes, and followed by a 1.5-minute re-
equilibration. Injection volume and column oven temperature are
2 mL and 50C, respectively. LLOQ and LOD are found to be 2 ng/mL
in 20 mL of plasma and 0.5 ng/mL, respectively. Plasma concentra-
tion data were analyzed using a noncompartmental method. The
pharmacokinetic parameters of hederacolchiside E after oral
administration of SKPC- B70M in male Sprague Dawley rats are
presented in Table 32. The pharmacokinetic data indicate the
nonlinear pharmacokinetic pattern.38
5.9. Rhizoma Corydalis Decumbentis (夏天無 xia tian wú)
Tetrahydropalmatine, protopine, and palmatine are the chemi-
cal moieties found in TCM herb, i.e., Rhizoma Corydalis Decumbentis.
It is commonly used for the treatment of hemiplegia, rheumatoid
arthritis, and infantile residual paralysis, to counteract the effects of
dementia and hepatotoxicity, and for pain relief.
A LC-ESI-MS with a positive ion mode was used for quantiﬁca-
tion and to determine the pharmacokinetic proﬁle for the three
alkaloids, tetrahydropalmatine, protopine, and palmatine, in rat
plasma. The system was equipped with a Diamonsil C18 column
(250 4.6mm, i.d., 4.6 mm, Dikma Technologies, Beijing, China) and
protected with an Easy Guard C18 guard column (5  4.6 mm i.d.,
5 mm, Dikma Technologies) maintained at 25C. The mobile phase
consisted of acetonitrile-water (40:60, v/v) containing 5mM
ammonium acetate and 0.2% glacial acetic acid. The ﬂow rate was
0.2 mL/min. The LOQ value was found to be 1.00 ng/mL. The mean
pharmacokinetic parameters of three alkaloids after oral adminis-
tration of Rhizoma Corydalis Decumbentis extract to rats are pre-
sented in Table 33. The pharmacokinetic data indicate that theTable 32
Pharmacokinetic parameters of hederacolchiside E after oral administration of
SKPC-B70M at a dose of 400 mg/kg in male Sprague Dawley rats.
Parameter SK-PC-B70M
100 mg/kg 200 mg/kg 400 mg/kg
AUC (mg h/mL) 0.56 ± 0.10 1.27 ± 0.27 6.46 ± 4.1
MRT (h) 9.46 ± 0.61 10.1 ± 0.41 16.1 ± 2.3
Tmax (h) 0.38 ± 0.14 5.69 ± 4.13 11.5 ± 9.1
Cmax (mg/mL) 0.07 ± 0.04 0.13 ± 0.08 0.36 ± 0.11
Tl1/2 (h) 31.1 ± 37.2 19.0 ± 18.5 28.9 ± 19.9
AUC¼ area under the concentration-time curve; Cmax¼ peak plasma concentration;
MRT ¼ mean residence time; Tmax ¼ time of peak plasma concentration; Tl1/
2 ¼ terminal elimination half-life.absorption of tetrahydropalmatine and palmatine is fast compared
to that of protopine, and elimination of palmatine is slow.396. Rhein
Rhein (RE, 1,8-dihydroxy-3-carboxyanthraquinone) is an active
ingredient extensively found in plants such as Aloe (蘆薈 lú huì),
Rhubarb (大黃 da huang), and Cassitoral L. It is currently used for
treating diabetic nephrosis in clinical practice and for broad phar-
macological activities, including antitumor, anti-inﬂammatory,
antibacterium, and renal protection properties. Esteriﬁcation of
free carboxyl group liberates two ester prodrugs of RE, i.e., rhein
methylate (REM) and rhein ethylate (REE).
A HPLC with Shimadzu RF-10A ﬂuorescence detector was used
to perform the comparative pharmacokinetic study of RE, REM, and
REE. The system was equipped with Shimadzu LC-10AT isocratic
pump, Shimadzu SIL-10AD auto-injector, HS chromatography
integrator, and a Hypersil ODS2 (4.6  250 mm, i.d. 5 mm, Dalian
Elite Analytical Instruments Co., China), column at 40C. Themobile
phase was composed of a mixture of acetonitrile: methanol: 0.3%
acetic acid (15:61:24, V/V/V) at a ﬂow rate of 1.2 mL/min. The
excitation and emissionwavelengths are set at 440 nm and 520 nm,
respectively. The retention time of RE, IS, REM, and REE was 4.2, 6.2,
6.8 and 8.6 minutes, respectively. LLOQ for RE, REM, and REE was
0.005, 0.020, and 0.020, respectively. The pharmacokinetic pa-
rameters of rhein are provided in Table 34. The carboxyl-
esteriﬁcation signiﬁcantly reduced the net exposure amount of
rhein in vivo, leading to its inaptitude in the development of drug
precursors of RE.40t1/2ka (h) 0.2 ± 0.1 4.1 ± 1.6* 3.0 ± 0.5**
t1/2 a (h) 1.1 ± 0.8 5.7 ± 1.6* 1.5 ± 0.6
t1/2 b (h) 3.2 ± 0.6 6.0 ± 1.7** 6.4 ± 1.0**
CL/F (L/h/kg) 0.78 ± 0.28 97.65 ± 66.61** 5.21 ± 0.51*
i.v. AUC0-∞
(h$mg/L)
80.28 ± 13.59 1.03 ± 0.76** 12.79 ± 0.96*
t1/2a (h) 0.1 ± 0.04 0.6 ± 0.4* 0.2 ± 0.1
t1/2b (h) 0.4 ± 0.1 3.8 ± 0.8** 2.9 ± 1.6*
CL/F (L/h/kg) 0.36 ± 0.11 0.93 ± 0.54 1.95 ± 0.68*
AUC0-∞
(h$mg/L)
2.40 ± 1.15 0.84 ± 0.40* 0.36 ± 0.092*
F abs (%) 33.5 15.2 2.9
*P < 0.05, **P < 0.01 versus RE group.
AUC¼ area under the concentration-time curve; Cmax¼ peak plasma concentration;
i.g. ¼ intragastric administration; i.v. ¼ intravenous; RE ¼ rhein; REE ¼ rhein eth-
ylate; REM ¼ rhein methylate; Tmax ¼ time of peak plasma concentration.
Table 35
Pharmacokinetic parameters in rats after intravenous administration 5 mg/kg.
Parameter Animal no. Mean SD
1 2 3 4
t1/2a (h) 0.586 0.155 0.109 0.131 0.245 0.228
t1/2b (h) 5.34 9.43 5.47 6.56 6.70 1.90
V (l/kg) 0.101 0.162 0.092 0.070 0.106 0.039
CL (l/(h kg)) 0.053 0.117 0.075 0.073 0.080 0.027
AUC0e24 (mg h/L) 89.06 36.24 60.76 59.46 61.38 21.62
AUC0e∞ (mg h/L) 95.09 42.62 66.44 68.05 68.05 21.45
AUC ¼ area under the concentration-time curve; SD ¼ standard deviation;
CL ¼ clearance; t1/2 ¼ half life.
Table 36
Pharmacokinetic parameters in rats after oral administration at 50 mg/kg.
Animal no. 1 2 3 4 Mean SD
t1/2a (h) 1.35 0.67 1.78 1.55 1.33 0.48
t1/2b (h) 1.53 8.41 1.95 1.59 3.37 3.37
t1/2 ka 0.046 0.491 1.225 1.310 0.768 0.606
AUC0e8 (mg h/l) 2.41 1.52 0.55 0.93 1.35 0.81
AUC0e∞ (mg h/l) 2.67 1.86 0.62 1.05 1.55 0.91
Bioavailability (%) 0.39 0.27 0.09 0.15 0.23 0.13
Tmax (h) 3.00 2.00 2.00 4.00 2.75 0.96
Cmax (mg/L) 1000.2 611.3 192.3 895.2 674.8 361.2
Where t1/2ka is for the half-life of the absorption.
AUC¼ area under the concentration-time curve; Cmax¼ peak plasma concentration;
SD ¼ standard deviation; Tmax ¼ time of peak plasma concentration;
t1/2b ¼ elimination half-life.
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Rhizoma Bolbostematts, widely used in TCM, is prepared from
the bulb of Bolbostemma paniculatum (Maxim.) (土貝母 tǔ bei mǔ)
Franquet. It possesses well-documented anticancer, antiviral, anti-
inﬂammatory, and immunosuppressive properties. Saponins are
considered as main bioactive constituents. Among them, tubei-
moside I is the main component in the saponins of R. Bolbostematts.
Tubeimoside I, a triterpenoid saponin isolated from the tubers of
B. paniculatum, showed potent antitumor and antitumor-
promoting effects.
A LC/MS method was used to determine the pharmacokinetic
parameters of tubeimoside I after administration via both intrave-
nous and oral routes. The systemwas equipped with a triple quad-
rupole mass spectrometer with Turbo-Ion-Spray ion source (MDS
Sciex Inc., Toronto, Canada) and a Waters Symmetry C18 reverse-Table 37
Pharmacokinetic parameters of ligustilide in rats after intravenous, intraperitoneal, and
Pharmacokinetic parameter Administration route and dose (mg/kg)
i.v.
15.6 14.9a
Tmax (h) e e
Cmax (mg/L) 13.19 ± 0.84 6.93 ± 0.60***
t1/2 (h) 0.31 ± 0.12 0.22 ± 0.07
AUC 0-m (mg/L)b 1.81 ± 0.24 0.79 ± 0.10**
Vd/F (L/kg)c 3.76 ± 1.23 5.62 ± 1.19
CL/F (L/h/kg)c 9.14 ± 1.27 20.35 ± 3.05**
MRT (h) 0.30 ± 0.07 0.19 ± 0.03
F (%) 45.7d
*p 0.05, **p 0.01, ***p 0.001, compared with i.v. dosing of the isolated ligustilide.
#p 0.05, ##p 0.01, ###p 0.001, compared with the lower i.p. dose of the isolated ligusti
AUC ¼ area under the concentration-time curve; Cmax ¼ peak plasma concentration; i.p.
Tmax ¼ time of peak plasma concentration; CL ¼ Clearance; Vd ¼ Volume of Distributio
Vd/F ¼ apparent volume of distribution based on the terminal phase.
a Dose of ligustilide in 100 mg/kg of Chuanxiong extract.
b Normalized with dose.
c Data represent Vd and CL in the case of i.v. dosing of the isolated ligustilide.
d Relative bioavailability compared with that of i.v. dosing of the isolated ligustilide.phase column (150  2.1 mm i.d., 3.5 mm, Waters Inc.) with a
SB-C18 guard column (20  4.0 mm i.d., 5 mm). The mobile phase
composed of a mixture of acetonitrile and water containing 5mM
sodium acetate (60:40, v/v). The ﬂow rate and column temperature
are 0.2 mL/min and 25C, respectively. The LLOQ for tubeimoside I
was20ng/mL in 0.1mL rat plasma. Thepharmacokinetic parameters
are described by using a two- compartmental model. The pharma-
cokinetic parameters in rats after intravenous administration are
presented in Tables 35 and 36. After the oral and intravenous
administration of tubeimoside I in rats, it shows limited absorption
in system circulation and was slowly eliminated.416.2. Rhizoma Chuanxiong (川芎 chuan xiong)
Ligustilide is the most abundant bioactive ingredient in Rhizoma
Chuanxiong, a TCM herb commonly used for the treatment of car-
diovascular ailments.
HPLC with an Agilent Series 1100 diode array detector was used
to determine pharmacokinetic parameters of ligustilide in rats. The
system was equipped with a Waters Symmetry C18 column
(150  4.6 mm i.d., 5 mm) coupled and a guard column (Waters
Spherisorb S5 ODS2,10 4.6mm i.d.). The samples are eluted using
a mobile phase containing 0.25% aqueous acetic acid, v/v (A), and
methanol (B). Oral bioavailability was estimated to be 2.6% at the
500-mg/kg dose. Ligustilide was monitored at 284 nm. The phar-
macokinetic parameters of ligustilide in rats after intravenous,
intraperitoneal, and oral administration are presented in Table 37.
Seven metabolites of ligustilide were identiﬁed, and three of them
were unequivocally characterized as butylidenephthalide, sen-
kyunolide I, and senkyunolide H. These three compounds also
occurred naturally in the herb and are reported to be bioactive.
The oral bioavailability of ligustilide was low (2.6%), which was
partly because of extensive ﬁrst-pass metabolism in the liver.426.3. Rabdosia rubescens (冬凌草 dong líng cǎo): Isodon rubescens
(Hemsl.) (冬凌草 dong líng cǎo)
Oridonin is a diterpenoid compound obtained from the Rabdosia
rubescens (Labiatae) plant. The herb has been used traditionally as a
digesting agent and anti-inﬂammatory agent. Oridonin has also
been detected in other herbs such as Isodon trichocarpus, Isodon
Japonicus, and Isodon shikokianus. It exhibits anti-inﬂammation,
antibacterial, and antitumor effects.oral administration (n ¼ 5).
i.p. p.o.
26 52 500
0.05 ± 0.02 0.08 ± 0.01 0.36 ± 0.19
7.48 ± 1.10*** 20.75 ± 2.55### 0.66 ± 0.23***
0.36 ± 0.05 0.44 ± 0.08# 03.43 ± 1.01***
0.93 ± 0.07* 1.77 ± 0.23# 0.047 ± 0.012**
6.54 ± 1.56 6.32 ± 1.81 1641.9 ± 121.6***
16.90 ± 1.21** 9.26 ± 1.04## 411.1 ± 145.7***
0.30 ± 0.05 0.41 ± 0.03 5.14 ± 1.56***
51.7 97.7 2.6
lide.
¼ intraperitoneal; i.v. ¼ intravenous; MRT ¼mean residence time; p.o. ¼ by mouth;
n; F ¼ Absolute bioavailability; t1/2 ¼ Half life; CL/F ¼ apparent plasma clearance;
Table 39
Pharmacokinetic parameters of prim-O-glucosylcimifugin and 4-O-D-glucosyl-5-O
methylvisamminol in rats after oral administration of Fangfeng extract.
Parameters Compounds
Prim-O-glucosylcimifugin 4-O-D-glucosyl-5-O-
methylvisamminol
T1/2 (h) 1.31 1.96
Cmax (ng/mL) 39.92 41.53
Tmax (h) 0.54 0.56
AUC(0et) (ng/mL h) 66.77 65.65
AUC(0e∞) (ng/mL h) 75.63 73.05
AUC¼ area under the concentration-time curve; Cmax¼ peak plasma concentration;
Tmax ¼ time of peak plasma concentration.
Table 40
Main pharmacokinetic parameters of swertiamarin after oral
administration of 20 mg/kg to rats (n ¼ 6, mean ± standard
deviation).
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and pharmacokinetic parameters after oridonin was injected in rat
plasma. The system was equipped with analytical DIKMA ODS C18
column (200 4.6mm,5mm)with aDIKMAODSC18 (4.612.5mm
i.d.) precolumn. The mobile phase was composed of acetonitrile-
0.01M ammonium acetate (0.5% acetic acid) (30:70, v/v). The ﬂow
rate, column temperature, and UV detector wavelength are 1.0 mL/
min, 25C, and 238 nm, respectively. After tail vein injection of
oridonin at 12.5 mg/kg dose in rats, oridonin in plasma are deter-
mined for a series of time pointswithin 24 hours. The LOD and LLOQ
are found to be 0.025 and 0.05 mg/mL, respectively. The two-
compartment open model was used to determine the plasma ori-
donin concentration-time curve. The pharmacokinetics parameters
calculated for intravenous administration of oridonin in rat are
presented in Table 38. The oridonin is distributed quickly and was
eliminated slowly in rats. The volumeof distribution indicates that it
might accumulate in certain organs or metabolize in the plasma.43
6.4. Saposhnikovia divaricata (Turcz) (防風 fang feng)
Fangfeng, the root of Saposhnikovia divaricata (Turcz.) Schischk.,
is listed as a high-grade drug, which means high effectiveness and
little toxicity in TCM. It is widely applied for headache, febrility,
vertigo, and arthralgia due to wind, cold, and dampness in China,
Japan, and other Asian countries. Prim-O-glucosylcimifugin and 4-
O-D-glucosyl-5-O-methylvisamminol are the two major active
chromones isolated fromFanfeng,whichpossess the analgesic, anti-
inﬂammatory effect and suppression of platelet aggregation, and
they may possess potential clinical applications such as treating
acute and dull aching, infarction, and anti-inﬂammatory conditions.
HPLS/MS was used to determine the pharmacokinetic parame-
ters and simultaneous detection of prim-O-glucosylcimifugin and
4-O-D-glucosyl-5-O-methylvisamminol in rat plasma and urine af-
ter single oral administration of Fangfeng extract. The system was
equipped with an Agilent TC-C18 column (150 4.6 mm i.d., 5 mm),
and with an ODS security guard column (10  4.6 mm i.d., 5 mm,
Zhonghuida Co., China). The gradient mobile phase was composed
of a methanol-water mixture containing 0.1% formic acid with a
ﬂow rate of 0.8 mL/min. The LLOQ of prim-O-glucosylcimifugin and
4-O-D-glucosyl-5-O-methylvisamminol was 1.0 ng/mL and 1.5 ng/
mL in plasma, 10 ng/mL and 15 ng/mL in urine, respectively. The
percent of two drugs excreted in the urine over the dose admin-
istered was 49.42% and 56.69% following oral administration. The
pharmacokinetic parameters of prim-O-glucosylcimifugin and 4-O-
D-glucosyl-5-O-methylvisamminol in rats after oral administration
of Fangfeng extract are presented in Table 39. In this study, other
than mentioned chromones two metabolites are also found, which
need to be studied in detail.44
6.5. S. japonica, S. mileensis (青葉膽 qıng ye dǎn), and S. chirata
Different plants of Swertia spp. S. japonica, S. mileensis, and
S. chirata (Gentianceae) are well known in TCM and other AsianTable 38
Pharmacokinetics parameters calculated from the
intravenous oridonin study in the rat.
Parameter Value
t1/2a (h) 0.12
t1/2b (h) 6.06
CL (L/kg/h) 1.56
AUC (mg h/mL) 7.96
Vd (L/kg) 1.83
AUC ¼ area under the concentration-time curve;
CL ¼ clearance; Vd ¼ volume of distribution.countries. These plants exhibit hepatoprotective, anti-
edematogenic, antihypolidemic, anti-spastic, anticholinergic, anti-
nociceptive, antibacterial, anti-inﬂammatory, and anti-oxidant
properties.
A LC-MS/MS method was used to determine pharmacokinetic
parameters and quantiﬁcation of swertiamarin in rats after oral
administration. The system was equipped with a G6410B triple
quadrupole mass spectrometer (Agilent), an ESI source, and an
Agilent ZORBAX ECLIPSE XDB-C18 (100  2.1mm i.d., 1.8 mm) col-
umn. The isocratic elution of mobile phase was composed of
methanol and water containing 0.1% acetic acid (25:75, v/v). The
ﬂow rate, column temperature, and internal standards are 0.2 mL/
min, 40C, and gentiopicroside, respectively. Pharmacokinetic pa-
rameters are calculated by using a noncompartmental model. The
LLOQ was 5 ng/mL within a linear range of 5e1000 ng/mL (n ¼ 7,
r2  0.994), and the LOD was 1.25 ng/mL (S/N  3). The pharma-
cokinetic parameters of swertiamarin after oral administration in
rats are presented in Table 40. The pharmacokinetic data revealed
that swertiamarin was rapidly absorbed into the circulation system
after oral administration but it showed a short half-life of 1.50
hours.45 The absolute bioavailability of swertiamarin is around
10.3%. After oral administration to rats, it was rapidly and widely
distributed in tissues. High concentrations were found in the liver
and kidney, indicating that swertiamarin was possibly absorbed in
the liver and eliminated by the kidney.466.6. Strychnos nux vomica L. (馬錢子 mǎ qian zǐ)
Semen Strychni is the dried mature seed of Strychnos nux vomica
L., a tree native in India. In classic Chinese Materia Medicas, the
herbal drug is listed as a toxic herb and its biological effects
(pharmacological and toxic effects) are dose dependent, needing to
be processed to reduce the toxicity before clinical uses required by
Chinese medicine prescriptions. Processed Semen Strychni isParameters Mean ± SD
t1/2z (h) 1.104 ± 0.229
Vz/F (L/kg) 9.637 ± 4.322
CLz/F (L/h/kg) 5.638 ± 2.151
AUC0e∞ (mg/L h) 3593.7 ± 985.4
MRT0e∞ (h) 1.929 ± 0.364
Tmax (h) 0.945 ± 0.136
Cmax (mg/L) 1920.1 ± 947.0
AUC ¼ area under the concentration-time curve; Cmax ¼ peak
plasma concentration; MRT¼mean residence time; SD¼ standard
deviation; Tmax ¼ time of peak plasma concentration; CL/F ¼
Apparent clearance; CL ¼ Clearance; t1/2 ¼ Half life.
Table 41
Pharmacokinetic parameters of chamaechromone in rats following intravenous
(5 mg/kg) and oral (100 mg/kg) administration.
Oral Intravenous
Parameters Mean ± SD Parameters Mean ± SD
Cmax (ng/L) 795.9 ± 14.6 C max (ng/L) 4300.7 ± 113.6
Tmax (h) 11.3 ± 0.8 t 1/2a (h) 0.47 ± 0.22
t1/2 (h) 30.0 ± 19.3 t1/2b (h) 19.5 ± 9.5
AUC0e60 (ng h/L) 6976.7 ± 1026.9 CL (L/(h kg)) 1202.1 ± 121.8
AUC0e∞ (ng h/L) 7388.6 ± 940.0 AUC0e48 (ng h/L) 3672.1 ± 225.4
CL z/F (L/(h kg)) 13,731.8 ± 1871.6 AUC0e∞(ng h/L) 4129.2 ± 231.8
Vz/F (L/kg) 277,476.2 ± 132,126.1 K10 (1/h) 0.72 ± 0.66
MRT0et (h) 18.5 ± 0.675 K12 (1/h) 1.67 ± 2.34
MRT0e∞ (h) 22.3 ± 4.9 K21 (1/h) 0.185 ± 0.261
F (%) 8.9 MRT0et (h) 8.1 ± 0.67
e e MRT0e∞ (h) 16.1 ± 3.6
All data are expressed as mean ± SD (n ¼ 6).
AUC ¼ are under the concentration curve; Cmax ¼ peak plasma concentration;
MRT ¼mean residence time; SD ¼ standard deviation; Tmax ¼ time of peak plasma
concentration; CL/F ¼ apparent clearance; CL ¼ clearance; F ¼ absolute bioavail-
ability; t1/2 ¼ half life.
Table 42
Pharmacokinetic parameters of magnesium lithospermate B after intravenous
administration in beagle dogs.
Parameter Dose/mg/kg
3 6 12
C0 (/mg/L) 24 ± 4 47 ± 12 107 ± 15
AUC0-tn (/mg$min/L) 109 ± 24 248 ± 55 582 ± 84
AUC 0-∞ (/mg$min/L) 109 ± 24 248 ± 55 583 ± 84
MRT0-∞ (/min) 16.3 ± 3.8 14.8 ± 2.9 14.0 ± 0.8
k10 (/h) 13.2 ± 2.1 11.6 ± 1.5 11.2 ± 1.3
k12 (/h) 5.2 ± 1.6 3.9 ± 2.2 3.1 ± 0.5
k21 (/h) 1.5 ± 0.5 1.4 ± 0.4 1.4 ± 0.3
V/L (/kg) 1.7 ± 0.5 1.6 ± 0.6 1.3 ± 0.3
T1/2a (/min) 2.2 ± 0.2 2.7 ± 0.5 2.9 ± 0.3
T1/2b (/min) 43 ± 9 42 ± 7 42 ± 10
CL(/mL/min/kg) 28 ± 5 26 ± 7 21 ± 3
n ¼ 6. Mean ± SD.
AUC ¼ area under the concentration-time curve; MRT ¼ mean residence time;
SD ¼ standard deviation; C0 ¼ initial plasma concentration; CL ¼ clearance;
t1/2 ¼ half life.
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traditional herbal medicines to treat nervous diseases, vomiting,
arthritis, and pain from trauma, and to promote blood circulation
and remove blood stasis. The most abundant alkaloids existing in
the processed Semen Strychni are strychnine and brucine, which
have been reported to possess analgesic, anti-inﬂammatory, and
antitumor effects despite their toxicity.
LC-ESI-MS with positive electrospray ionization was used for
simultaneous determination of strychnine, brucine, and pharma-
cokinetic parameters after oral administration of processed Semen
Strychni to Wistar rats. The system was equipped with a Waters
Symmetry TM C18 column (100  4.6 mm i.d., 5 mm,) kept at 30C.
The mobile phase was composed of methanol, 20mM ammonium
formate, and formic acid (32:68:0.68, v/v/v) with a ﬂow rate of
0.4 mL/min. The mean maximum plasma concentrations of
strychnine and brucine detected in the rats are 54.93 and 4.95 ng/
mL, respectively. Higher sensitivity was offered, with LLOQ of 0.5
and 0.1 ng/mL for strychnine and brucine, respectively, requiring
only 0.1 mL of plasma.47 When both strychnine and brucine are
individually incubated with rat liver S9 fraction, strychnine N-oxide
and brucine N-oxide are the two metabolites that result.48
6.7. Stellera chamaejasme L. (狼毒 lang dú)
Stellera chamaejasme L. (Thymelaeaceae) is one of the toxic TCM
listed in the Chinese Pharmacopeia. In recent years, it has also been
used for the treatment of intestinal, gastric, and pulmonary cancers.
Chamaechromone is a major biﬂavone constituent in dried roots of
S. chamaejasme. The plant also shows anti-inﬂammatory, antiviral,
cytotoxic, and antioxidant activity because of its biﬂavones and
ﬂavonoids contents.
A LC-MS with a positive ESI in MRM mode was used to deter-
mine the pharmacokinetics and absolute bioavailability chamae-
chromone in rat plasma. The systemwas equipped with an Xbridge
TM C18 column (2.1  50 mm i.d., 3.5 mm, Waters). The mobile
phase consisted of methanol-water containing 0.1% formic acid
with a gradient elution starting at 5% methanol and progressing
linearly to 90% methanol over 5.0 minutes, then returning to 5%
methanol. Total run time was 6 minutes. The mobile phase was
delivered at a ﬂow rate of 0.4 mL/min. Rats receive 100 mg/kg
chamaechromone by oral administration or intravenous injection
of 5 mg/kg via the tail vein to determine the plasma concentration
of chamaechromone in rats. The LLOQ of chamaechromone was
8 ng/mL. The pharmacokinetic parameters of chamaechromone in
rats following intravenous and oral administration are provided in
Table 41. The absolute bioavailability of chamaechromone was
found to be 8.9%. Its poor absorption may be due to poor perme-
ability through the intestinal epithelial membrane and efﬁcient
metabolism in the intestine, which is a common reason for low
bioavailability of ﬂavanoid compounds.49
6.8. Salvia miltiorrhiza Bge (丹參 dan shen)
The Chinese medicine, danshen, is the dried root and rhizome of
Salvia miltiorrhiza Bge (Labiatae). Traditionally, danshen is believed
to be effective in eliminating blood stasis, relieving pain, promoting
blood ﬂow, and stimulating menstrual discharge as well as easing
the mind. Magnesium lithospermate B (MLB) has been found to
have strong antioxidative and free-radical scavenging effects.
The LC-MS/MS method was used to determine the pharmaco-
kinetics of MLB after intravenous administration and also detect the
serum concentrations of MLB in beagle dogs. The system was
equippedwith CAPCELL PAKC18 column (50 2mm i.d., 5 mm) and
a Phenomenex C18 guard column. The mobile phase composed of
56% water (containing a mass fraction of 0.5% formic acid) and 44%acetonitrile at a ﬂow rate 0.25 mL/min for an isocratic elution at
room temperature. The pharmacokinetic parameters of MLB after
intravenous administration in beagle dogs are presented in
Table 42. This study indicates that MLB is rapidly distributed and
metabolized in tissues and at a high dose, it shows saturated dis-
tribution.50 The catechol O-methyltransferase is responsible for
formation of four (M1-M4) methylated metabolites in rats. The
rapid and high biliary excretion levels of these metabolites sug-
gested that they could undergo enterohepatic circulation and that
they might thereby be largely responsible for the pharmacological
effects of MLB.51
6.9. Salvia miltiorrhiza Bunge (丹參 dan shen): Salvia miltiorrhiza
Bge (丹參 dan shen)
R-(þ)-b-(3,4-dihydroxyphenyl)-lactic acid [named danshensu
(Dhpl)] and protocatechuic aldehyde (Pal) have been considered
themajor active constituents of Salvia miltiorrhiza Bunge (Labiatae).
Danshen (roots) of the plant has been used in TCM to treat coronary
diseases, particularly angina pectoris and myocardial infarction.
This plant also exhibits anticoagulant, antiarteriosclerotic, anti-
inﬂammatory, and antihypoxic qualities.
The HPLC/UV method was used to determine the pharmacoki-
netic parameters of Dhpl and Pal. The systemwas equipped with an
Table 44
Pharmacokinetic parameters of tetrandrine after single oral administration
of 50 mg/kg in six Sprague Dawley rats.
Parameter Tetrandrine (50 mg/kg)
Tmax (h) 6.0 ± 1.8
Cmax (ng/mL) 237.1 ± 95.9
AUC(0e72) (mg/mL) 6279.2 ± 2411.5
AUC0/∞) (mg/mL) 7002.7 ± 2528.0
T1/2 (h) 20.6 ± 3.7
ke (L/h) 0.034 ± 0.006
AUC ¼ area under the concentration-time curve; Cmax ¼ peak plasma con-
centration; Tmax ¼ time of peak plasma concentration; Ke : elimination rate
constant; t1/2 ¼ half life.
Table 45
Pharmacokinetic parameters after silibinin administration (100 mg/kg, intrave-
nously and 500 mg/kg by mouth) for blood.
Parameters Silibinin (100 mg/kg i.v.) Silibinin (500 mg/kg p.o.)
Unconjugated Total Unconjugated Total
AUC (min mg/mL) 5.5 ± 0.73 35.5 ± 5.9 0.26 ± 0.07 7.17 ± 1.42
Cmax (mg/mL) 256 ± 36 239 ± 19 8.5 ± 2.6 76 ± 15
t1/2 (min) 68 ± 7.2 105 ± 29 12.2 ± 1.8 77 ± 3.2
Tmax 0 8.2 ± 4.5 11 ± 1.8 30 ± 4.7
Data are expressed as mean ± standard error of the mean (n ¼ 6).
AUC¼ area under the concentration time curve; Cmax¼ peak plasma concentration;
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and protected by RP18 (5 mm) guard column (Dikma, Beijing,
China). The mobile phase consisted of 0.02% phosphoric acid-
acetonitrile (91:9, v/v). The ﬂow rate was 1 mL/min and the UV-
vis detector was set at 280 nm. The LOQ for Dhpl and Pal was
found to be 1.43 and 0.12 mg/mL, respectively. The pharmacokinetic
parameters are determined by using non- compartmental analysis.
The pharmacokinetics parameters of Dhpl and Pal after oral
administration are presented in Table 43. The double-peak phe-
nomenon was observed in these pharmacokinetic data and it may
be due to the hepatoenteral circulation and redistribution in tissues
phenomenon.52
6.10. Stephania tetrandra (粉防己 fen fang jǐ)
Tetrandrine is an important bisbenzyl isoquinoline alkaloid
isolated from the bulbous root of Stephania tetrandra S Moore
(Menispermaceae) of TCM. It is widely use as an anti-inﬂammatory,
antiallergic, antioxidant, and antiﬁbrogenetic agent, as well as in
immunomodulation and inhibition of platelet aggregation In
addition to these pharmacological effects, tetrandrine also exhibits
liver toxicity in dogs when administered in high doses for a rela-
tively long period.
The LC/MS/MS method was used to determine the pharmaco-
kinetic parameters of tetrandrine in rat plasma when administered
as a single oral dose (50 mg/kg) in six Sprague Dawley rats. The
system was equipped with a Dikma Diamonsil-C18 analytical col-
umn (4.6  150 mm i.d., 5 mm, Dikma Technologies, Beijing, China)
at 35C. The mobile phase consisted of acetonitrile-methanol-
ammonium formate aqueous solution (20mM) containing 0.3%
formic acid (20:30:50, v/v/v). The ﬂowand LLOQ are 0.3ml/min and
5 ng/ml respectively. The pharmacokinetic parameters after single
oral administration standard in female Wister rats are presented in
Table 44.53
6.11. Silybum marianum L. (水飛薊 shuǐ fei jì)
Silybummarianum L., also known as milk thistle, is widely use in
traditional European medicine. Silymarin, a polyphenolic ﬂavonoid
isolated from milk thistle, primarily consists of four isomeric mix-
tures of active ﬂavonolignans: silychristin, silydianin, and two
groups of diastereoisomeric ﬂavonolignans, silibinin, and iso-
silibinin. Silymarin is clinically useful for the treatment of toxic
hepatitis, fatty liver, cirrhosis, ischemic injury, radiation toxicity,
and viral hepatitis. It is a strong antioxidant capable of scavenging
unconjugated radicals.
The LC method was used to measure unconjugated silibinin and
total silibinin in rat plasma and bile. The systemwas equipped with
a LiChrosorb RP-18 column (250  4 mm i.d., 5 mm, Merck) pro-
tected by guard column (Purospher STAR RP-18e, 5 mm) at room
temperature (24 ± 1 C). The mobile phases consisted of
acetonitrile-10mMmonosodium phosphate (pH 5.45 adjusted withTable 43
Pharmacokinetics parameters of Dhpl and Pal after oral administration, dose 10 g/kg.
Parameter Radix Salviae miltiorrhizae extract
Dhpl Pal
MRT (h) 3.43 ± 0.07 4.31 ± 0.06
AUC 0-∞ (mg$h/mL) 396.82 ± 17.27 15.64 ± 0.66
Calibration curve
(mg/mL)
1.43e228.48 a determination
coefﬁcient (r) of 0.996 (n ¼ 8)
0.12e7.94 a determination
coefﬁcient (r2) of 0.994
(n ¼ 8)
LOQ (mg/mL) 1.43. 0.12
AUC ¼ area under the concentration-time curve; LOQ ¼ limit of quantiﬁcation;
MRT ¼ mean residence time.orthophosphoric acid) (50:50, v/v). The ﬂow rate and detection
wavelength are 1 mL/min and 288 nm, respectively. The oral
bioavailability of silibinin in rats was estimated to be 0.73%. Phar-
macokinetic calculations are performed on each individual set of
data using by noncompartmental method. The AUC was calculated
according to the linear trapezoidal method. The pharmacokinetic
parameters after silibinin administration are presented in Tables 45
and 46. The polyphenolic silibinin potentially go through Phase II
conjugated reaction with glucuronidation. The conjugated metab-
olites are more water soluble, and they are possible in due course
excreted in the urine and bile. It leads to poor bioavailability of
silibinin. The absolute oral bioavailability of silibinin in rats was
found to be approximately 0.95%. This may be due to the high
reactivity with Phase II conjugation and poor absorption rate. The
distribution ratio of AUCbile/AUCblood of silibinin suggests that the
hepatobiliary elimination of silibinin may be regulated by active
transport.54
7. Steroidal glycoalkaloids
Solanum spp. are well known for their steroidal glycoalkaloid
properties, and solamargine is one of the steroid alkaloid glycosides
present in them. Solamargine is useful as an antitumor agent in
cancers of the colon, lung, and breast.
The HPLC method coupled with Shimadzu LCMS-2010A quad-
rupole MS by an ESI interface was used to determine the pharma-
cokinetic parameters of solamargine in rats. The system wasi.v. ¼ intravenous; p.o. ¼ by mouth.
Table 46
Pharmacokinetic parameters after silibinin administration (100 mg/kg, intravenous
and 500 mg/kg by mouth) for bile.
Parameters Unconjugated Total
AUC (min mg/mL) 11.1 ± 2.84 1202 ± 186
Cmax (mg/mL) 517 ± 85 7910 ± 2080
t1/2 (min) 33 ± 8.3 97 ± 28
Tmax 5.1 ± 1.0 50 ± 18
AUC bile/AUC blood 3.1 ± 0.95 30 ± 9.4
Data are expressed as mean ± standard error of the mean (n ¼ 6).
AUC ¼ area under the concentration time curve; Cmax ¼ peak plasma concentration.
Table 48
Pharmacokinetic parameters of FK-3000 [6,7-di-O-acetylsinococuline] iso-
lated from Stephania delavayi.
Pharmacokinetic parameters Mean ± SD
Tmax (h) 0.20 ± 0.06
T1/2 (h) 1.79 ± 0.09
Cmax (ng/mL) 251.9 ± 168.2
MRT (h) 1.61 ± 0.33
AUC0e6 h (ng h/mL) 209.3 ± 42.0
AUC0e∞ (ng h/mL) 245.7 ± 40.5
AUC ¼ area under the concentration time curve; Cmax ¼ peak plasma
concentration; MRT ¼ mean residence time; SD ¼ standard deviation;
Tmax ¼ time of peak plasma concentration.
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5 mm)with a gradient elution of themobile phase system consisting
of acetonitrile (A) and 0.02% formic acid (B). The temperature of the
column and auto-sampler was kept constant at 40C and 10C,
respectively. Pharmacokinetic parameters in rats are estimated by a
compartmental method. The studied method was successfully
applied to analyze rat plasma samples after intravenous injection of
solamargine at 1.0, 2.0, and 4.0 mg/kg in rats, supporting its
applicability to biosample assay. The pharmacokinetic parameters
after a single intravenous dose of 1.0, 2.0, and 4.0 mg/kg sol-
amargine in rats are presented in Table 47. The pharmacokinetic
data indicate that elimination or biotransformation of solamargine
occurred relatively quickly in rats.557.1. Stephania cepharantha (金線吊烏龜 jın xian diao wu guı)
FK-3000 [6,7-di-O-acetylsinococuline] is isolated from Stepha-
nia delavayi Diels (地不容 dì bù rong) and Stephania cepharantha. It
exhibits antiviral action against the human immunodeﬁciency vi-
rus and also anticarcinogenic action in e breast cancer. FK-3000 also
exhibits cytotoxic (apoptosis induction) and cytostatic (cell cycle
arrest) effects.
A LC-MS with positive ESI was used to determine the pharma-
cokinetic parameters of FK-3000. The system was equipped with
reverse-phase Gemini column (3.0  150 mm i.d., 5 mm, Phenom-
enex) with Security Guard TM (3.0  4.0 mm i.d., Phenomenex).
The mobile phase is composed of acetonitrile and 0.1% formic acid
(85:15, v/v) at a ﬂow rate of 0.2 mL/min. The injection volume was
30 mL. The assay just described was applied to a pharmacokinetic
(PK) study of FK-3000 using oral administration at a dose of 20 mg/
kg in male rats. The LLOQ was found to be 10 ng/mL with a wide
linear dynamic range from 10 ng/mL to 10,000 ng/mL. An optimized
chromatographic run time of 9 minutes per sample yielded sym-
metric peaks for FK-3000. AUC0-t was calculated by a linear trape-
zoidal method. The pharmacokinetic parameters of FK-3000 [6,7-
di-O-acetylsinococuline] isolated from Stephania delavayi are pre-
sented in Table 48.567.2. Tripterygium wilfordii Hook F (TWHF) (雷公藤 lei gong teng)
Triptolide is a highly oxygenated diterpenoid triepoxide, is the
major component responsible for the immunosuppressive and
anti-inﬂammatory effects of Tripterygium wilfordii Hook F (TWHF),
and serves as the quality control standard for TWHF. It is commonly
used in the treatment of rheumatoid arthritis and other autoim-
mune diseases. Triptolide has a small margin between therapeutic
and toxic doses and shows serious toxicity in the digestive, uro-
genital, and blood circulatory systems when its levels rise beyond
the upper limits.Table 47
Pharmacokinetic parameters after a single intravenous dose of 1.0, 2.0, and 4.0 mg/
kg solamargine in rats (n ¼ 5).
Parameters Mean ± SD
1.0 mg/kg 2.0 mg/kg 4.0 mg/kg
The plasma
concentration at
5min (C5) (ng/mL)
538.54 ± 278.79 1094.37 ± 694.87 2483.40 ± 272.89
Cl (L/kg h) 3.81 ± 0.68 4.10 ± 1.23 3.97 ± 0.44
Vd (L/kg) 20.16 ± 10.34 19.78 ± 12.55 15.68 ± 6.19
t1/2 (h) 3.54 ± 1.50 3.29 ± 1.52 2.76 ± 1.10
AUC0et (ng h/mL) 242.41 ± 65.68 482.36 ± 138.07 947.74 ± 124.76
AUC0e∞ (ng h/mL) 270.50 ± 54.66 526.92 ± 161.72 1018.91 ± 117.26
AUC ¼ area under the concentration time curve; SD ¼ standard deviation;
Cl ¼ clearance; Vd ¼ volume of distribution; t1/2 ¼ half life.The LC/MS method was used to determine the pharmacokinetic
parameters of triptolide. The system was equipped with a Zorbax
Extend-C18 analytical column (4.6  150 mm i.d., 5 mm, Agilent
Technologies) protected by a ODS guard column (Security Guard,
Phenomenex) at 40C. The mobile phase was composed of aceto-
nitrile/methanol/0.05% triethylamine aqueous solution (20:50:30,
v/v/v) at a ﬂow rate of 1 mL/min. Under these conditions, triptolide
eluted at approximately 3.2 minutes and the internal standard at
4.0 minutes. All measurements are carried out using the negative
ion atmospheric pressure chemical ionization (APCI) mode. LLOQ
was found to be 1 ng/mL in rat plasma. The pharmacokinetic pa-
rameters of triptolide in rats after oral or intravenous administra-
tion of triptolide are presented in Table 49. The current
pharmacokinetic data reveal that triptolide was metabolized
extensively, eliminated rapidly, and also showed that the toxicity
produced by the triptolide was lag behind the exposure
concentration.577.3. Tripterygium wilfordii (雷公藤 lei gong teng): Tripterygium
wilfordii Hook F (TWHF) (雷公藤 lei gong teng)
Triptolide, a diterpenoid triepoxide compound, isolated from
the roots of Tripterygium wilfordii Hook F (Celastraceae, TWHF) is
also commonly known as Thunder God Vine. In TCM it is used to
treat some autoimmune disorders such as rheumatoid arthritis,
systemic lupus erythematosus, and skin diseases.
The liquid chromatography with atmospheric pressure chemical
ionization mass spectrometry (LC-APCI-MS) method was used to
determine the pharmacokinetic parameters of triptolide. The sys-
tem was equipped with a Zorbax Extend-C18 analytical column
(4.6  150 mm i.d., 5 mm) protected by a ODS guard column
(Security Guard, Phenomenex) at 40C. The mobile phase
composed of acetonitrile/methanol/0.05% triethylamine aqueous
solution (30:50:20, v/v/v) at a ﬂow rate of 0.75 mL/min. Triptolide
eluted at approximately 3.3 minutes and the internal standard
(prednisolone) at 4.0 minutes. The LOQ and total run time are
0.5 ng/mL and 5 minutes, respectively. The pharmacokinetic study
of six beagle dogs following intragastric administration at a single
dose of 0.05 mg/kg triptolide solution are presented in Table 50.587.4. Verbascum sinuatum (毛蕊花 mao ruǐ hua), Orobanche rapum
(列當 lie dang), Cistanche salsa G. Beck (肉蓯蓉 rou cong rong), and
Plantago psyllium L (車前 che qian), Olea europaea (橄欖 gǎn lǎn)
Acteoside is a phenylethanoid glycoside having water-soluble
polyphenolic compounds, which are widely distributed in many
medicinal plants, including Verbascum sinuatum, Orobanche rapum,
Cistanches salsa (C.A. Mey) G. Beck, and Plantago psyllium L, Olea
europaea. Acteoside shows neuroprotective action and attenuated
scopolamine-induced memory impairments in mice. Acteoside and
Table 49
Pharmacokinetic parameters of triptolide in rats after oral or intravenous administration of triptolide.
Parameter Oral dose/mg/kg Intravenous dose/mg/kg
0.6 1.2 2.4 0.6
ka (L/min) 0.37 ± 0.17 0.39 ± 0.16 0.251 ± 0.09 e
ke (L/min) 0.03 ± 0.01 0.04 ± 0.02 0.03 ± 0.01 e
V/F (L/kg) 0.32 ± 0.34 0.33 ± 0.30 0.22 ± 0.17 1.27 ± 0.25
T1/2 ka (min) 2.19 ± 0.92 2.06 ± 0.83 3.00 ± 0.87 e
T1/2 ke (min) 21.70 ± 3.00 16.81 ± 5.24 20.40 ± 3.75 15.10 ± 4.44
AUC(0etn) (mg/L min) 7057.14 ± 1826.04 10445.67 ± 3178.42 14538.98 ± 5636.58 9791.18 ± 585.88
Tmax (min) 11.00 ± 2.24 10.00 ± 0.00 10.00 ± 0.00 e
Cmax (mg/L) 254.00 ± 47.34 446.65 ± 112.86 537.33 ± 143.34 e
CL/F (L/min/kg) 0.06 ± 0.02 0.06 ± 0.02 0.06 ± 0.03 0.06 ± 0.01
n ¼ 6, mean ± standard deviation.
AUC ¼ area under the concentration-time curve; Cmax ¼ peak plasma concentration; Tmax ¼ time of peak plasma concentration; CL/F ¼ apparent clearance; Ke ¼ elimination
rate constant; Ka ¼ absorption rate constant; t1/2 ¼ half life.
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culture of rat cortical cells.
The LC with amperometric detection and microdialysis sam-
pling method was used to determine pharmacokinetic proﬁle
protein-unbound acteoside in rat blood. Acteoside and dialysates
was separated by using a Phenomenex Gemini column
(150  2.0 mm i.d., 5 mm) with its guard column (10  2.0 mm i.d.).
The mobile phase comprised acetonitrile-50mM monosodium
phosphate (pH 2.8, adjusting with 85% orthophosphoric acid)
(17:83, v/v), and the ﬂow rate of the mobile phase was 0.2 mL/min.Table 50
The pharmacokinetic study of six beagle dogs following i.g.
administration at a single dose of 0.05 mg/kg triptolide solution.
Parameter Values
Cmax 28.03 ± 11.76 ng/mL
Tmax 0.96 ± 0.30 h
MRT0tn 3.00 ± 0.54 h
T1/2ka 0.50 ± 0.38 h
Cmax ¼ peak plasma concentration; MRT ¼ mean residence
time; Tmax ¼ time of peak plasma concentration.
Table 51
Pharmacokinetic parameters of acteoside in rats after 10 mg/kg
administration.
Parameters Estimated
A (mg/mL) 71.9 ± 30.9
B (mg/mL) 2.9 ± 0.5
a (L/min) 0.14 ± 0.03
b (L/min) 0.02 ± 0.004
t1/2a (min) 5.0 ± 1.2
t1/2b (min) 28.5 ± 4.7
AUC (min mg/mL) 592.3 ± 124.7
Vss (mL/kg) 277.7 ± 185.8
Cl (mL/min/kg) 17.7 ± 4.5
Data expressed as mean ± standard deviation (n ¼ 6); t1/2, a:
distribution half-life; t1/2, b: elimination half-life.
AUC¼ area under the concentration-time curve; Cl¼ clearance;
Vss ¼ volume of distribution at steady state.
Table 52
Estimated pharmacokinetic parameters after single oral administration of 300 mg/kg gin
Parameter 6-Gingerol 8-Gingerol
AUC(0-t) (mg/mL/h) 1.689 ± 0.38 0.177 ± 0.0
MRT(0-t) (h) 1.776 ± 0.502 1.845 ± 0.1
T1/2 (h) 3.574 ± 1.994 1.08 ± 0.4
Tmax (h) 1.167 ± 0.764 0.833 ± 0.2
Cmax (mg/L) 0.933 ± 0.545 0.092 ± 0.0
CL/F (L/h/kg) 57.43 ± 22.359 60.59 ± 8.8
AUC ¼ area under the concentration-time curve; Cmax ¼ peak plasma concentration; MRT
plasma clearance; t1/2 ¼ half life.The LOD and LOQ for acteoside were found to be 2 ng/mL and 5 ng/
mL, respectively. The pharmacokinetic parameters of acteoside in
rats after 10 mg/kg administration are presented in Table 51. The
pharmacokinetic data indicate that acteoside was unable to be
detected in the brain dialysate and it also was rapidly distributed in
the body.59
7.5. Zingiber ofﬁcinale (薑 jiang)
Ginger, the dried rhizome of Zingiber ofﬁcinale Roscoe (Zingi-
beraceae), is not only a popular spice and ﬂavoring agent in a va-
riety of foods, but also is an important dietary supplement for
nausea and motion sickness. In TCM, fresh or processed ginger has
been used for the treatment of many ailments. Ginger mainly
contains essential oil and oleoresin. Oleoresin is the nonvolatile
pungent component, and the major constituents of oleoresin
have been identiﬁed as 6-gingerol, 8-gingerol, 10-gingerol, and
6-shogaol, which is the corresponding dehydration product of
6-gingerol.
A HPLC-MS method with positive ionization interface was used
to determine the pharmacokinetic parameters of ginger oleoresin.
The system was equipped with an Agilent Zorbax StableBond-C18
column (4.6  50 mm i.d., 1.8 mm) and the temperature was set at
30C. Themobile phases consisted of 0.1% formic acid water (A) and
acetonitrile (B). The ﬂow rate and injection volume are 1.0 mL/min,
and 2 mL, respectively. Pharmacokinetic parameters are estimated
using noncompartmental analysis. LLOQ of 6-gingerol 0.0104,
8-gingerol 0.00357,10-gingerol 0.00920, and 6-shogaol 0.00738 mg/
mL. The pharmacokinetic parameters after single oral administra-
tion of 300 mg/kg ginger oleoresin in ﬁve rats are presented in
Table 52. 6-Gingerol shows 90% plasma protein binding in rats and
also extensive ﬁrst-pass metabolism. 6-gingerol could be readily
conjugated with glycuronic acid in the alimentary tract in vivo. It is
also the reason for the low bioavailability. The 6-gingerol glucuro-
nidewas identiﬁed from bile and urine as the primarymetabolite of
rats orally administered 6-gingerol. As per pharmacological and
toxicological consideration, Phase II metabolism of gingerols isger oleoresin to ﬁve rats.
10-Gingerol 6-Shogaol
25 0.222 ± 0.021 0.14 ± 0.011
69 1.84 ± 0.263 1.932 ± 0.592
39 1.576 ± 1.03 1.127 ± 0.745
89 0.361 ± 0.141 1 ± 0.866
18 0.156 ± 0.012 0.111 ± 0.041
49 154.898 ± 101.852 133.652 ± 14.032
¼mean residence time; Tmax ¼ time of peak plasma concentration; CL/F¼ apparent
P. Mehta et al. / Journal of Traditional and Complementary Medicine 5 (2015) 207e227226important. In plasma, 6-gingerol was found in its glucuronide form
and 8-gingerol, 10-gingerol, and 6-shogaol were distributed into
blood in free form.60
8. Conclusion
Numerous herbal medicines as phytoformulations, phyto-
chemicals, nutraceuticals, and functional food currently are avail-
able to improve health. Active principle obtained from the plants
are the moribund source of treatment against the wide range of the
diseases and in near future it may supersedes the synthetic moi-
eties. These herbal medicines are not restricted to a particular
ailment. Because these medicines are used with increasing fre-
quency to improve health, it is essential to know the pharmacoki-
netic proﬁle of the aliment being treated. ADME plays a central role
in promoting more rational use and to map pharmacological ac-
tions of such herbal aliments. This pharmacokinetic proﬁle acts as a
blueprint for the medicinal plant. These data help justify the ther-
apeutic, toxicological, and clinical value of herbal medicines. Recent
research corroborates traditional claims and justiﬁes use of herbal
medicines for the welfare of the human beings. This necessitates
further study of the many facets of these wonderful traditional
herbal medicines. To support herbal medicine research in the near
future and to expand activities, the current review will help those
who are involved in natural product research.
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